b e h r n g e r n g e l h e agility value innovationc n e n enquired agility means us c u r g e right thing strategic decisions demand great flexibility courage involved discussion integration new animal health takes courage take new roads together objectives effects new people strategy focus art seeing clearly best worlds boehringer ingelheims new animal health overview n e e f r h e b g products brands prospects p c u r e little things dr michael mark team research anna vgh tells life rare autoimmune ing active ingredients treatment disease scleroderma cardio metabolic diseases c r e v transformation meets tradition visit bi x boehringer ingelheims new digital lab digitising full swing move worldwide boehringer ingelheim sought found consistent imaginative answers change image gallery f r e g h eye big picture boehringer ingelheims scientific department estab lished one hundred years ago oday spirit research lives innovation unit focus patients interview dr oliver reu approaches go beyond actual medications turning point guest contribution explains china important location research driven pharmaceutical h e b e f b h companies around world w r l imprint integration new animal health full swing course set growthe x p l r e h e n e r c v e c n e n annual report smart whenever see symbol magazine start video straight correspond ing smartphone tablet e p download layar app smart phone tablet open app e p hold device would like watch additional video content tap screen scan keep still device scan video open directly play e p wish view video full screen tap video playing e p press close symbol exit video n e n c r n f r n e e r n goal new digital lab bi x create innovative digital solutions researchdriven pharmaceutical company h ttpsplaygooglecomstore h ttpswwwapplecomios appstore h e l l e h n g horses help scleroderma patient anna vgh cope diseasee x p l r e h e n e r c v e c n e n annual report smart whenever see symbol magazine start video straight correspond ing smartphone tablet e p download layar app smart phone tablet open app e p hold device would like watch additional video content tap screen scan keep still device scan video open directly play e p wish view video full screen tap video playing e p press close symbol exit video n e n c boehringer ingelheim glantcr aen f r n e e r n goal new digital lab bi x boehringer ingelheim one worlds leading create innovative digital solutions pharmaceutical coremseaprcahndireivsen pharmaceutical company eur billion founded total net sales ingelheim eur familyowned day httpsplaygooglecomstore httpswwwapplecomios appstore billion expenditure research development employees worldwide total net sales e u r e u r e u r b l l n b l l n l l n h e l l e h n g horses help scleroderma patient anna vgh cope disease human pharmaceuticals animal health biopharmaceuticalsour company improving health quality life patients goal researchdriven pharmaceutical company boehringer ingelheim focus diseases satisfactory treatment option exists date company therefore concentrates develop ing innovative therapies extend patients lives animal health boehringer ingelheim stands advanced prevention familyowned since established boehringer ingelheim one pharmaceutical industrys top companies employees create value innovation daily three business areas human pharmaceuticals animal health biopharma ceuticals boehringer ingelheim achieved net sales almost billion euros rd expenditure exceeding three billion euros corresponded per cent net sales familyowned company boehringer ingelheim plans generations focuses longterm success rather shortterm profit company therefore aims organic growth resources simultaneous openness partnerships strategic alliances research everything boehringer ingelheim naturally adopts responsibility towards mankind environment l g kreativitt w h g l e n f r u role agility play boehringer ingelheim tradition boehringer ingelheims initial success familyowned company based industrial production acids move massproduced chemical raw materials patentprotected pharmaceutical specialties required building successful research operation called understanding new customer class physicians example agility turned us leading research driven pharmaceutical company today serve inspiration us current transformation healthcare market also adapt needs finance healthcare system christian boehringer chairman shareholders committee l g ahow much influence agility integration new animal health business animal health agile company currently engaged building boehringer ingelheim new unit bringing two successful companies together given us opportunity regroup around truly core business one cornerstones common culture agility beyond agility embedded agile must allow boehringer ingelheim process flexibility adapta bility increase contribution patient called order meet require company health offering new ments customers position innovative therapeutic options expand leading position breakthroughs answer medical highly competitive market successfully needs human well market animal side using new technology collaborating partners even intensely networks dr joachim hasenmaier able manage ever larger data member board managing directors successful market enable us target medicine responsibility animal health crucial company b usiness unit precisely individual patient agile agility required many making products even areas one excellent customer effective increasing benefit understanding agility react society changing customer perceptions expectations another agility react changing market conditions hubertus von baumbach finally agility respond competi chairman board managing directors tors actions strategies important increase competitiveness allan hillgrove member board managing directors responsibility human pharma business unit u r f n e l ga hwhow agile boehringer ingelheim employees secure companys future change new normal change changing often agility whole journey start end drive companys unclear agility agility organisation employees comes financial success mean b oehringer play agility opposite structure fact often requires ingelheims innova disciplined approach decision tive capability agility pre condition making combined accountability economic success intrapreneurship powerful reason want recognise recipe success ever faster changing internal agility required every day external conditions early also journey idea draw right conclusions dr andreas neumann innovation indispensable matter acting rapidly member board managing directors timely integration new information necessary diligence thus also responsibility human resources allowing us learn failures overcome future challenges compete build small wins step step successfully deliver best achieve breakthroughs services customers dr michel pairet michael schmelmer member board managing directors member board managing directors responsibility innovation unit responsibility finance l g acourage g l n e e c u r g e right thing strategic decisions demand great flexibility courage people involved animal health organisations boehringer ingelheim sanofi merged two corporate cultures many different nationalities found way single melting pot boehringer ingelheims new animal health business unit rogier biemans site director pirbright uk originally boehringer ingelheim organisation vanessa mariani global commercial operations integration lead former merial employee discuss bring together best worlds l g arogier transferred rules dress code stricter vanessa mariani boehringer ingelheim site weesp conversations formal rogier biemans met october netherlands pirbright uk get know people loosen ingelheim work vanessa left atlanta usa boehringer ingelheims came ingelheim much mariani noticed certain formality new animal health courage take ingelheim well like business unit appreciate framework rules biemans wasnt easy tell lives different every day saying goodbye colleagues flexible despite hard would really liked take formality weve created space try stay lot relaxed touch life moving interact people uk treating approach different situations well vanessa spent mariani move game life north america working changer atlanta worked merial germany challenging im part boehringer ingelheim ive living ingelheim since march mariani work global corpo stay march rate world rare find someone extended business trip hasnt interacted husband still lives atlanta try cultures positive part fly home every four weeks move ingelheim culture way ive felt welcomed biemans jobs also keep us boehringer ingelheim organisation busy theres really time miss old integration team ingelheim ways general fantastic experience mariani thats true change personally really people also boehringer ingelheim location im still touch merial general two companies colleagues worked atlanta trying integrate two businesses people ingelheim form single entity right vanessa mariani amazing welcoming vanessa mariani moved ingelheim theres nothing id change biemans process still ongoing germany last spring global commercial operations integration continue throughout lead transferred boehringer vanessa living rather rural upcoming months differences ingelheim merial area going far regarding corporate structure responsible strategic planning huge merial multinational public marketing excellence originally mexico city mariani lived much mariani originally mexico company boehringer ingelheim life new york city city lived new york city privately held global organisation moving atlanta years ingelheim definitely change ingelheim like havent really suffered mariani combine two cultural shock thing takes businesses developed new vision little bit get used sundays driven conviction rogier biemans stores closed germany animals enrich human life vital rogier biemans currently integration process boehringer ingelheim 's site director pirbright uk moving size town taken common set beliefs greater london area august time get used people dutchman worked produc also different whats special boehringer ingelheim merial tion manager boehringer boehringer ingelheim headquarters unique corporate ingelheim site weesp netherlands biemans years culture corporate culture experience life sciences pharma biemans whenever visit ingelh eim mean ceutical research development feel people correct value manufacturing e g r u c e e n l g abiemans people interact relates underlying values boehringer ingelheim structured way working people always correct respectful creates certain atmosphere determines people interact mariani culture whether society large corporation behaviour everyday life written code really live underlying values build culture main differences cultures merial boehringer ingelheim mariani found merial lot lax open structur ing daily business probably fact previously joint venture gave organisation great freedom operate biemans agree beginning year global operations conference merial headquarters lyon threeday conference lunch together everybody waiting vanessa mariani rogier biemans agenda sent arrived exchanged views lyon still waiting agenda boehringer certainly informal ingelheims corpo improvised boehringer ingelheim rate culture people used mariani yes many people coming lax environment tight framework little bit shock youve worked various loca tions culture differ place biemans boehringer ingelheim theres common corporate culture certain elements unique location country hugely influences way people interact type location also plays role whether production site office l g amariani feel animal health mariani right combining two different corporate general people passionate creating respect different parts cultures isnt easy industry social purpose team boss example teambuilding activities make work fulfilling dr name usually transition easier right thing animals people establishes certain distance industry people work really hard approachable person mariani deal across locations countries find works team room sanofi boehringer ingelheim us whether hes doctor concluded different countries day right thing specific engineer architect really one events integration workshops animal health matters us hes got commit team ingelheim organ ment respect work ise quarterly social activities like going mariani ive working field title dinner almost years per spective always intrinsic biemans also feel things biemans transferred animal health ive found changing germany uk onboarding good people time ive ingelheim formal today nice open really straight intrinsic overall boehringer forward pirbright everyone gets ingelheim culture always ask card birthday didnt selves best approach previous site weesp like new longterm gain fit ideas always good take best overall strategy try worlds use right thing right reasons long term refreshing theres link stereotypes arise today tomorrow working many different cultures dont always see companies biemans british strong biemans agree humour dont think thats stereo example products make type though appreciate vigorous uk vaccines footandmouth exchange views sometimes rogier biemans moved disease fmd sell govern enjoyable sometimes little bit boehringer ments department ingelheim site weesp much veterinary public health lyon netherlands pirbright uk vaccines change peoples lives mariani ingelheim melting pot vanessa mariani came many people products funda many different nationalities atlanta usa mental even fundamental ingelheim cant stereotypes work sometimes realise many different people place one main differences englishspeaking countries germa biemans every individual different ny people work together fact one comes certain address german use country doesnt pigeonhole last names formal word formal informal germans retain certain distance heated cool mexicans find mariani work people biemans uk hardly use columbia spain spanish peoples last name atmosphere speaking countries joke relaxed animal health also little others accents colloquial bit casual areas isms good humour pharmaceutical industry production locations particular less formal biemans happily make like opinion boundaries jokes youre commu established first last names nicating level mat ters underlying factors underlying respect e g r u c e e n l g ajoachim larsen role people strategy manager responsible development implementation people strategy works boehringer ingelheims copenhagen office k e c u r g e k e n e w r g e h e r whats goal new people changes new people important strategy boehringer ingelheim strategy entail management implementing worldwide since employees larsen takes courage beginning take new roads together adapt larsen supporting individual organisation changing environ larsen faced challenge departments business areas subsidi ment employees want know rapidly adapt position aries answering today positions roles responsi effectively competitive develop necessary competencies bilities company today also increasingly volatile market tomorrows challenges basis tomorrow therefore essential us environment well achieve good understanding hr acknowledge yes weve objectives company right strengths weaknesses got even agile respond employees right competencies describe competencies need accordingly end successful right time weve established prepare employees business allow us create new jobs strategic basis people accordingly put special emphasis keep existing ones vice versa strategy aid structured also providing appropriate training talented highly motivated people holistic approach aspire identify implementation people strategy help us keep company employees competencies thus sharpen ability handle flourishing key future success future challenges l g ao u r f c u h e r f e e n g c l e r l focus framework helps us concentrate efforts needed e g r u c e e n l g awho want work towards achieve goal core leitbild boehringer ingelheims commitment agility independent serve mankind met quickly act open mind face familyowned company preferred partner admired competi internal external transformation intend remain tor earch respond drivers w e driven desire n umber one animal health changes active experimen serve mankind improving human n umber one biopharmaceutical tation animal health contract manufacturing c hallenge status quo w e feel responsible commu n umber one value share assumptions others nities respectful brands one human pharma political bias resources q uickly turn data insights w e plan generations focus aspire grow sales insights actions longterm performance billion euros l earn open mind rarely make mistake twice create value accountability innovation even ambiguous circumstances customers always demonstrate ownership decisions actions w e develop breakthrough therapies health care solutions areas r ole model boehringer ingelheim unmet medical need values always say focus w e excel innovation deliver saying think highest quality drive catalyst unlock ake timely decisions well competitiveness balanced analysis intuition w e believe partnering success potential particularly tough situations sustainable economic r uthlessly prioritise drive boehringer health company execution excellence discipline collaboration ingelheim ctively give seek feedback powered leverage others strengths people deliver results develop every individual w e nurture diverse collaborative open environment intrapreneurship appeals best people together customers create w e driven results working innovative ideas respond changing integrity passion markets w e treat respect trust empathy grow together erve needs customers patients turning innovative ideas business results ake smart risks leveraging possible opportunities including resources talents emonstrate winning spirit creating cando attitude positive energy among others eliver high quality results despite challenging conditions l g ausing collective power year passed since boehringer ingelheim acquired competitor sanofis animal health business merial integration well underway everything set growth boehringer ingelheim intends make animal health business market leader e g r u c e e n l g aa gg ii ii tt yy nn ee ee dd ss cc oo uu rr aa gg eeboehringer ingelheim vision boehringer ingelheim researchdriven pharmaceu animal health global market positions tical company wants create world animals longer suffer avoidable diseases targeted prevention work help stop occurring first place boehringer ingelheim convinced create animals healthy humans world healthier realise vision boehringer animals ingelheim acquired merial animal health business pharmaceutical longer company sanofi january pets equine acquisition brings together two highly suffer compatible portfolios strengthen avoidable boehringer ingelheims competitiveness field animal health following diseases integration merial net sales swine veterinary animal health doubled public provide one fifth health total group net sales around employees business unit worldwide boehringer ingelheim offers animal health products markets merial boehringer ingelheim fit together like pieces jigsaw puzzle combination strengths boehringer ingelheim enables boehringer ingelheim take avian cattle leader livestock segment merial full advantage markets potential brought leadership companion animals potential enormous global leader cats dogs forecasts predict net sales global animal health market double billion euros part reflects growing world parasiticides vaccines population worlds pop ulation reached nine billion sales split species current demand meat animals doubled even tripled healthy increasing globalisation humans stronger links different countries continents mean healthier infectious animal diseases may become even frequent livestock future companion another trend people animals spending increasingly large sums money pets dogs cats domestic animals long since become members family l g aboehringer ingelheim optimally yet competition fierce positioned integrated product animal health market research portfolio features development key factor future products dogs cats horses pigs success growth around scien cattle poultry following acquisi tists support staff conducting tion merial boehringer ingelheim research sites globally secondbiggest player glob order stem spread diseases al animal health market goal even occur well next years clear boehringer ingelheim core segments vaccines parasiticides aims become market leader products pharmaceuticals boehringer animal health today ingelheim intends expand pet dogs cats horses pigs company already leader health care diagnostics live cattle poultry areas vaccines parasiticides therapeutics segments able boehringer ingelheim also offer customers even broader number one pets equine swine solutions future field veterinary public health aims catch poultry cattle acquisition brings together two highly compatible portfolios strengthen boehringer ingelheims compe titiveness field animal health e g r u c e e n l g athe new animal health business focusing prevention boehringer ingelheim long tradition prevention animal health following integration merial thanks strategic partnerships external partners novozymes boehringer ingelheim able offer even innovative solutions future partnership novozymes boehringer ingelheim novozymes alliance currently test order boost expertise phase set market launch field prevention boehringer boehringer ingelheim leader livestock segment merial ingelheim entered strategic brought leadership companion partnership danish biotech com animals cats dogs nexgard combat parasites pany novozymes march next ten years new partners dogs get fleas owners soon face want work together develop challenge pests burrow deep live therapeutic products poultry dogs fur skin hatcheries novozymes like jump surroundings responsible research untreated fleas cause health development work boehringer problems dogs humans ingelheim market differen ticks makes preven tiated solutions first product tion important line floramax probiotic product novozymes portfolio thanks integration merial boehringer ingelheims portfolio probiotics becoming increasingly includes nexgard family important alternatives antibiot medicines nexgard administered ics could also play beefflavoured chew major role preventive health living launch first oral medication microbes positive impact treat fleas ticks dogs intestinal flora balance poultry currently bestselling pet medica animals thereby providing tion animal health industry specific health benefits cases certain markets boehringer ingelheim produce distinct compounds recently launched nexgard spectra help immune system adds protection dogs mature leading healthier gut certain internal parasites first probiotic product data file l g e g r u c e e n l g courage g l n e e c u r g enothing ever anna vgh since learned suffers scleroderma rare autoimmune disease anna give found way happy life despite condition little things anna sitting mother mother awful must hospital waiting room disease asks time petite young woman later annas doctor tells auburn hair nervous anxious suffering scleroderma might lie ahead eight years ago experiencing severe pain rare disease scleroderma also known weeks suffers particularly systemic sclerosis causes swelling painful sensations stomach scarring connective tissue many hands well breathing cases lungs organs worst mornings evenings gradually also suffer scarring one knows causes become lifethreatening patients explain annas skin changes disease affects around two million suddenly feels different rough people worldwide mainly women thicker doctor unable account age family frightened back world completely fell hungarian woman living small apart anna recalls even though town szombathely simply wants doctor assured many patients know happening maintained good quality life everyone knows senses disease felt though would never seriously ill sitting happy ever simply couldnt hospital waiting imagine someone could lead nice minutes slowly pass poster catches life disease like says anna annas eye heading scleroderma years old time displays facts disease lot research order find well images people suffering faced everything found anna shocked leans absolutely terrifying found l g apositive examples find body else suffering disease talk things completely time noted experiencing symptoms mobility declined breath rapidly give hobbies fell ill gone gym several times week exercise spinning bike came point could longer manage simply didnt strength really frustrated says anna also get used regularly taking medicines attending hospital checkups well suddenly extremely restricted even entirely normal everyday situations couldnt even use credit card since much strain hands take purse horses sense mood without say anything feels luckily include riding anna turns special antidote horses like therapy anna several anna nevertheless learned help come times week spends time terms disease cope disease noticed riding school outside szombathely many important things rides regularly one still capable says sports still engage kept job quality manager horses sense mood without important col say anything really leagues continued treat normally today im much grateful comforts days dont feel able job little things think good social life change result future much whenever days spends sun disease family still feels afraid tells ive already horses often forgets important thing mother worst else illness place means absolute brother sister never leave side happen naturally relaxation worst thing tests consultations aware disease every day anna would could longer doctors friends also give lot dominate life really think ride eventuality neverthe strength important know take medicines less plans continue visit disease cant take away hospital appointment horses would despite lung capacity enough reason go meantime anna become per cent breathing exercises anna decided go public happy maybe even hap medicines help many things story order encourage pier diagnosis simply longer possible sufferers would like make clear e g r u c e e n l g amore scleroderma scleroderma systemic sclerosis ssc rare far incurable disease characterised hardening skin connective tissue affects around two million people worldwide three times women men mainly midlife lung diseases common manifestation systemic sclerosis particularly serious patients develop pulmonary fibrosis extent boehringer ingelheim leader respiratory medicine conducting active research potential fatal consequences fibrotic lung diseases years global initiative scleroderma inside story boehringer ingelheim pursuing goal educating society whole providing information disease interested end company collects inspiring stories patients world publishes brief portraits lives website wwwboehringeringelheimcom portraits may video interviews photo series sufferers read anna long looked stud farm keeps horses paddocks patients cope would like huge amount space disease time learn horses enjoy also gives sense make clear freedom rides across progression disease paddocks part serious effects initiative seeking scare people contrary goal alone show patients disease determine lives find way alone coping eight portraits forgotten poster patients seven countries waiting room seeing horror currently featured website scenarios makes worse instead hearing people live happy lives spite university michigan scleroderma program wwwmedumichedusclerodermapatients disease people like anna sclerodermahtm l g acreativity g l n e e c r e v transformation meets tradition wild sketches brightly painted office walls furcovered stools bi x boehringer ingelheims new digital lab looks like work spaces startup san francisco berlin goal innovative digital solutions researchdriven pharmaceutical company bi x thereby marks beginning transformation whole company digitisation boehringer ingelheim full swing l g aeven projects fail indirectly lead success later learn something anyone looking new bi x company founded summer digital lab boehringer still comparably small ingelheim campus ingelheim staff around however new faces germany stands good chance join team every month mid getting lost minute walk around talented tech specialists main gate building located working digital lab edge little wood rather company seeks experienced experts unassuming almost oldfashioned bring indepth know outside inside ledge industry methodical look like startup although digitisation well pioneers also desks people work wherever necessary passion implementing suits time foyer initiatives visions conviction lounge corner large wooden formally bi x subsidiary table kitchen anyone boehringer ingelheim digital lab spontaneous idea instantly jot de facto startup synergies marker pen writable parent company create benefits walls even large windows make everyday work easier views greenery bright postit independent company bi x benefits notes stuck ideas greatly freedom startup lost technology impressive also triedandtested almost every room processes globally leading pharma giant touchscreen addition ceutical company example unconventional tools small comes contracts approval process building blocks case quick tangible es says schmelmer gives models called people time bi x whole new world meant specifically boehringer ingelheim elsewhere way working distinguishes ingelheim site people predominantly bi x clearly rest dress traditional businesswear lab coats company tech experts work overalls dr daniel hach opens accordance latest agile doors bi x trainers tshirt planning methods yearold one first people fact always employed digital lab respon lead instant success part sible part fourman management plan failure allowed bi x states team daytoday operations schmelmer bi x consciously visit october meet michael work highrisk projects hard schmelmer head bi x implement average half well boehringer ingelheims chief projects successful setbacks information officer cio part learning process v e r c e e n l gawanted innovations first bi x projects bi x developments go three cycles michael schmelmer explains first phase ideas closely aligned business parent company example bi x team developed software researchers make easier list good ideas analyse data latest scientific insights long whole world identify possible windows bi x turned relationships example certain protein pinboards concentrations could recognised possible therapeutic approach medication development speeded team currently second wave generating ideas developing new appro aches still connected boehringer ingelheims business disruptive thereby capable opening new business areas bi x team instance developed app digital early detecti alzheimers disease aim determine analysing speech whether person showing early signs disease alzheimers research linked traditional businesses boehringer ingelheim app offers service yet exist form whats nobody else done anything like michael schmelmer bi x aims lead boehringer ingelheim future says third wave team wants go new digital movement team still take assignments working innovative solutions enterprise potential shake market schmelmer puts come time bi x mature start topics gauge processes place team knows bi x works address highrisk matters however kind might something schmelmer wants reveal yet cfo boehringer ingelheim since january l g asuccessful implementation thing counts even projects fail indirectly lead success later learn something learning mistakes part bi xs dna mission statement literally writ large foyer take challenges every day take risks make mistakes pride play rules bi x manifesto states members staff developed mission statement together new approach every morning boehringer ingelheim like fact bi x team agrees team decides priorities wants achieve wants day work members plans says schmelmer lot boehringer ingelheim large corporations particular since needed terms digital transfor usual staff levels mation recalls first august organisation make strategy decisions weeks collected ideas quickly together also always easy became clear wanted action schmelmer accept decisionmak basics ing freedom staff bi x bi x independent beginning needed terms learning process handsoff subsidiary boehringer ingelheim office space technologies staff try intervene dayto focuses innovative digital company look like day running bi x solutions healthcare sector ingelheim really right place digitisation strategic importance quickly became clear bi x boehringer ingelheim bi x would need near parent company hopes offer even better startup works closely companys headquarters bi x team treatment options patients together three found suitable building former future goal combine boehringer ingelheim businesses guest restaurant time expertise global research driven human pharmaceuticals animal used occasionally internal pharmaceutical company techno health biopharmaceuticals training sessions modification took logical knowhow integrate four months bi x team moving newly acquired knowledge june classic pharma business lasting bi x develops product team includes maria apsolon basis boehringer ingelheim sees prototypes solutions estonia joined bi x powerful development potential tests pilot phases software specialist october whole organisation frontend developer digitally customers mind without support implements design developed top man agement whole boehringer ingelheim ideas currently working companys combined aspiration invested platform pharmaceutical however would possible researchers collect structure million euros says schmelmer exchange data started bi x birth bi x came spring bi x frontend developer idea structuring digital serious pressure says looking initiatives boehringer ingelheim back work hard lot desire grew rapidly end around worth developing products small team digitalthinking col make difference people leagues external strategists opinion makes bi x stand formed jointly develop bi x special way working concept hach still external consult worked bi x number set tech experts work flexibly using ant board discussed increase around mid scrum method start v e r c e e n l gaproject phase generally lasts two need right people bi x spreading entrepreneurial spirit weeks one clearly defined order successful says schmelmer innovative working techniques measurable goal individual project wants draw talented staff digital lab throughout entire steps flexible however location exciting content company one thing clear emerge course process work us people actually qualities associated start apsolon says project staff bring change agile flexible resultdriven divided new teams compris working solutions could work also factors success ing data scientists scrum masters potentially save lives future traditional company like frontend backend developers bi x teams plans almost boehringer ingelheim user experience designers get limitless current year want together daily standup implement many projects member staff briefly explains possible boehringer ingelheim priorities day end help us build ideas hach project phase team looks says initial support also back together results decides impact direction whether direction project needs adjusting progress seen members staff foyer future bits bytes status project displayed three large screens boehringer ingelheim aims fully exhaust digital potential thereby team sets goals respec build multiple initiatives selection tive week schmelmer says theres immense performance culture bi x everyone wants make difference really feel independent subsidiary bi x promotes smart healthcare solutions counter balance hard business areas human pharmaceuticals animal health biopharmaceuticals work team enjoys regular time order develop digital business idea business areas turn bi x outs week team goes digital lab helps clearly define idea delivers prototypes dinner together trying various restaurants area something new products failure expressly allowed decisive trying new going quite right project technologies thereby possibly also reaching goal indirectly table football foyer comes different ideas something done business model healthcare innovation go whatever winner decides innovation team located one human pharma business unit works jokes apsolon closely experts various therapeutic areas experts thus frontend developer recognise needs early work jointly partners targeted solutions estonian team colleagues come countries like usa concentrate intensively digital healthcare solutions based modern spain austria netherlands hungary information communication technology see interview dr oliver reu bulgaria bi x office language english accident many different nationalities come together work boehringer accelerate ingelheim focused diversity initiative accelerate boehringer ingelheim employs innovative inclusion years company potential employees worldwide everyone submit proposals certain diversity major driver innovation growth digital innovations interdisciplinary jury decides submitters international talent however must implement proposals within desired timeframe international demand undoubtedly mainly three months subsequently report experiences even people would top heads name ingelheim projects meantime failed important everybody learns preferred job location thats one see text hololens project greatest challenges facing bi x l g ao n h e v e w r l w e past year boehr inger ingelheim dr iven var ious project cover ing var ied topics however something common openminded employees w ith sense responsibilit consistentl invent ivel sought answer change found v e r c e e n l ga creativityt h e p w e r f n f l u e n c e r already used social networks actively harnessing power influencers still new phenomenon companies boehringer ingelheim japan taken concept tailored researchdriven pharmaceutical company young employees known change champions started pushing ahead new global principles working together rolled agility accountability intrapreneurship aai see aai change champions connected informal networks work facilitators influencers storytellers frontrunners without instructions develop goals initiatives seek dialogue colleagues practical approach developed favourable dynamic inspired sides surprise second generation aai change champions already starting blocks l g aa f r k k afrika kommt africa coming initiative allows specialists africa exchange views managers major german corporations effect change together one founding members research driven pharmaceutical company boehringer ingelheim since supported initiative foster diversity pharmacist simon manyara kenya participated programme boehringer ingelheims site ingelheim germany eight months since fellowship simon continued support various projects within corporate strategy development boehringer ingelheim l e r n n g u n e r ta n p e n b e e r important patient unfulfilled needs research tangibly applied help address needs order get bottom questions boehringer ingelheim launched scorecard project usa march eight crossdisciplinary teams look far beyond therapeutic areas traditional researchdriven pharmaceutical company work close cooperation patients improve clinical trials gain better understanding patients needs done employing questionnaires oneonone patient interviews well moderated online discussions digital consultation platform v e r c e e n l gav r u l p g pigs romping boehringer ingelheims corporate site ingelheim germany animals seen people wearing special goggles microsoft hololens allows interactive images projected onto immediate environment hand movements herd pigs touching even hear gentle grunt tool like could future help farmers administer medicines animals however still long way aim boehringer ingelheim fraunhofer institute software system technology isst test threemonth pilot project opportunities new technology offer employee department requested research innovative dynamic digital approach via companys special accelerate internal platform boehringer ingelheim agreed request supported development pilot project euros l g g e h e r f e r n g c l n n vat n two days october participants variety countries gathered boehringer ingelheim campus ingelheim germany joint objective drive future success making health mmh initiative founded boehringer ingelheim ashoka mmh fosters social innovation around world explores unconventional partnerships business models encourages boehringer ingelheim employees mmh convention gave participants opportunity network inform innovative local international mmh projects unleash new cooperations three pillars provided framework cocreation bond social responsibility business social innovation social entrepreneurs mmh network fostering entrepreneurial intrapreneurial thinking changemaker programme innovative way develop leadership skills convention delivered exhibition different workshops success stories panel discussions interviews v e r c e e n l gaa c c e l e r n g h e e v e l p e n f u n n c l g h e r p e combination immunooncology therapy concepts essential part boehringer ingelheims cancer research strategy focuses turning tumours hidden immune system visible therefore enable bodys immune system recognize attack tumours approach commonly described turning cold tumours hot tumours researchers focusing novel approa ches might result breakthrough treatments patients difficulttotreat conditions lung cancer g astrointestinal cancers despite recent treatment advances lung cancer still number one cancer killer gastrointestinal tumours increasing importance last years among frequent cancers asia bring results oncology research patients quickly boehringer ingelheim collaborating sarah cannon cancer research institute us conduct clinical trials expertise partner supports researchdriven pharmaceutical company identifying right patients optimally supporting clinical trials meaningful results high quality may achieved timely manner boehringer ingelheims goal remains always accelerate development innovative cancer treatments patients high therapeutic need l g ar g e f e l e b e v e r open unbiased way thinking requires corresponding working environment boehringer ingelheim reshaped ridgefield site usa inclusive campus completely redesigned diversity inclusion mind workstations parking places bathroom facilities another example redesigned auditorium wheelchair access technology support employees hearing impairments project instigated implemented ridgefield workforce clear example changes teams able bring everyone pulls together c v e r p f n e n v r n e n often difficult correctly interpret symptoms rare disease idiopathic pulmonary fibrosis ipf however fast diagnosis decisive denmark virtual reality game helping doctors hone awareness example interpreting various lung noises virtual world investigating healthy lung tissue ipf sufferer boehringer ingelheims brand communication team denmark developed game record time last year could employed first time annual conference danish lung specialists v e r c e e n l gat w e lv e c e n w e lv e n h todays modern workers desire flexibility healthy worklife balance innovative companies like boehringer ingelheim identify transformation turn programmes remote year support inspiration remote year organised development programme brings together mix international professionals free lancers entrepreneurs live work community twelve global cities whole year remote year promises provide personal professional growth giving participants opportunity learn one another immerse different local cultures business ecosys tems annemadeleine kleinwchter global senior manager leadership development boehringer ingelheim first boehringer ingelheim employee take part programme annemadeleines itinerary covers emerging mature markets consists cities eg prague lisbon kyoto kuala lumpur chiang mai buenos aires mexico city picture annemadeleine colleagues work kyoto japan l g aa b u c n r u c n p r j e c speed name game boehringer ingelheims new manufacturing facility respimat pocket inhaler sant cugat spain go production september groundbreaking ceremony took place june path point involved several hurdles project engineering teams ultimately able stay schedule obtain planning permission local authorities future boehringer ingelheim manufacture million cartridges respimat inhaler every year also package finished product sant cugat v e r c e e n l ga l g ai n v e f r r k e p e n began october dubai united arab emirates first stroke center set support boehringer ingelheim meta stroke initiative quickly expanded rest meta region consisting middle east turkey africa region every second counts treatment stroke patients lives initiative aims creating stroke centers excellence region spreading knowledge experience locally result initiative thrombolysis rate increased per cent initiative established per cent initiative focuses countries board including specialists eight countries together boehringer ingelheim health authorities objective heighten public awareness stroke initiative meanwhile succeeded increasing number treated stroke patients around incidence stroke rise around world meta stroke initiative part boehringer ingelheiminitiated angels initiative cooperates leading stroke organisa tions experts goal improve acute stroke care patients worldwide w h e n w b e c e n e year change boehringer ingelheims animal health business two former competitors became one previous strangers became colleagues supervisors order make transition seamless possible staff boehringer ingelheim animal health philippines organised camp one project team building activity calling mental agility everybody understood merger would mean everyone would operate outside comfort zone project success new animal health business philippines already enjoyed significant increase sales second half year v e r c e e n l gas h w n g p v e h e lt h p c communicating results highlyscientific registration events interest lifeyears gained patients trials transforming complex data laymans terms taking boehringer ingelheim medication becoming ever challenging order lose calculations assumptions transparent sight overall picture big data boehringer ingelheim scientifically sound initially hicap calculator set train development inhouse app used boehringer ingelheims internal specialists health impact care patients hicap enables medical affairs marketing hicap far measurement many patients worldwide simply innovative gadget app translates highly helped researchdriven pharmaceutical complex technical details based clinical trial results companys products committed team statisticians drug sales data broken country easily data experts taken task result app understood graphic elements shows great converts abstract concept public benefit contribution boehringer ingelheim benefiting accessible visuals hicap calculator based patients health r shiny technology gives estimated number prevented l g athe big picture g l n e e f r e g h eye big picture boehringer ingelheim science department founded years ago future nobel prize winner heinrich wieland ensured done futureoriented way today companys scientific activities bundled innovation unit continues embody companys spirit research although scientists michael mark things quite differently compared wielands time still lots similarities l g amichael mark noticed one born wieland cousin thing straight away every helene wife company founder one gave friendly albert boehringer onwards n eed welcome says looking back advised boehringers company first day boehringer ingelheim champions development new medicines biberach germanys upper swabian time age region yearold pharma believe mark started biberach cology graduate joined research gifted chemist wieland pushed idea department boundaries research plantbased feeling belonging alkaloids developed cardiovascu want follow remained day mark says lar medicine cadechol boehringer respects lot happened since ingelheim later lobelin company grown enor emergency treatment respiratory mously mark participated arrest shock conditions countless research projects advancing conducted regular basic research become head cardiometabolic students assistants research department within university munich degree innovation unit never one would hardly possible minute regretted choosing boehringer medicine developers ingelheim ingelheim job appealed based company straight away exactly wanted able discover new mechanisms action develop new medicines theres nothing appealing trained pharmacist today mark responsible work researchers biberach well people ridgefield connecticut usa organises various research projects internally partnership collaboration partners reviews ideas put forward working groups withdraws staff projects increases number substance looking particularly promising boehringer ingelheim able work fundamental issues necessary foresight mark says get time required responsibility least spirit heinrich wieland lasting effect companys science department celebrated centenary great chemist later nobel prize winner beginning heinrich wieland right laboratory h g e r e e n l g adr michael mark staff evaluating digital images fluores cence laser microscope nine countries differing edu cation expertise including special ists human medicine molecular biology employ gene analysis modern microscopes access available scientific databases probably even soon able simulate effects side effects using software promised nascent discipline systems biology regards research activities boehringer ingelheim also builds collaborations external partners universities well startup compa nies please see guest contribution ruiping xiao peking university mark came current field research thanks phd supervisor wellknown pharmacologist hermann ammon working diabetes start th century research young protg addition pursuing academic doctoral studies worked careers young chemists usually worked mechanisms insulin release advisors pharmaceutical compa boehringer ingelheim biberach nies order make living external able mark directly linked studies lecturers wieland much better initially focussed glinides connected integrated boehringer work substance class stimulates insulin ingelheim colleagues secretion pancreas industry thus kind fundamental emerged repa glinide put founding father todays researchers market prandin company also include mark ssues protracted phase mark thinks great heinrich colleagues focussed lipid wieland today mark sometimes wishes necessary metabolism atherosclerosis new could engage finding solutions phase diabetes research began freedom straightfor fores ight one first projects mark ward manner possible initiated search dpp inhibitors drug development complex substances inhibit involving many different disci breakdown specific hormone plines regulations course intestine eventually lowering blood necessary least ensure patient sugar result work safety says mark hand active substance linagliptin trajenta researchers today naturally many launched one opportunities disposal bestselling medicines licensed novo nordisk team mark works scientists jointly marketed eli lilly company boehringer ingelheim portfolio l g athe next significant medicine fact individual scientists marks work played major role wieland successor sglt inhibitor called jardiance georg scheuing developed entire active substance empagliflozin medicines practically reading scientific articles late would longer possible todays occurred mark phlori world mark says fields research zin initially isolated simply big individual root bark apple trees lowers blood topics complex making sugar levels causes glucose specialist knowledge expertise excreted urine mecha many necessary mark convinced nism known long time even today need champions mark team among first modern believe idea want use knowledge develop follow medicine treat diabetes therefore pharmaceuti currently colleagues applied knowledge rare genetic working treatments compli mutation carriers also cal research cations diabetes addressing excrete sugar urine knew damage causes eyes people mechanism constantly kidneys vascular system wherever apparent disadvantages accord possible also wants investigate ingly sglt inhibitors ask root causes diabetes develop efficacious welltolerated long ment well done term says mark although many patients avoid disease diseases experts sceptical team liver focus cardio able pursue idea jardiance metabolic research lipid metabo also major success today lism plays major role boehringer jardiance diabetes research iseases need ingelheim already one step ahead ers drew plantbased source mark believes never looked material one wieland would improved diabetes glucose metabolism probably aware wieland isolation always part represented last generation herapies bodys entire metabolic events boehringer ingelheim developers something else also remained work natural active substances applica fundamentally unchanged since best student georg scheuing wieland era boehringer ingelheim headed science department tions close ties scientific community onwards guided company supports basic research draws synthetic substances p ossible factors attract talented people major step forwards mark work company mark calls colleagues approached develop talent management supporting ment jardiance similar way promising young scientists supervising wieland time preparing new tasks idea substance could work playing active role international pursued application research networks final diabetic patients modern pharma analysis different ceutical research constantly ask wieland regularly recommended patients best students promis diseases need improved therapies ing scientists boehringer ingelheim applications possible phd supervisor search therapeutic approaches ernst boehringer younger son full knowledge disease companys founder understanding fundamental biological mechanism well expertise arrive suitable molecules jointly marketed eli lilly company h g e r e e n l g afrom office biberach germany michael mark responsible work research colleagues boehringer ingelheim heinrich wieland developed lobelin emer gency medication respiratory arrest shock conditions phlorizin sglt inhibitor empagliflozin jardiance derived originally comes root bark apple tree today diabetes medicine jardiance great success l g athe right questions f c u n p e n h g e r f e e n l gawhat kinds projects dr oliver reuss specifically studied molecular biology worked management dr reuss let give exam consultancy completing ple currently working smart postdoc joined addon classic stethoscope boehringer ingelheim small digital microphone fitted inside initially stethoscope linked worked corporate business smartphone algorithms analyse analysis driving patients lung sounds help strategy development doctor identify respiratory disorders forwards core business one example idiopathic pulmonary fibrosis rather rare became head business always easily diagnosed disease model health one requires early treatment care innovation arent major technology companies pioneers digital environ ment opportunities boehringer ingelheim expect products services boehringer dr reuss course theres mega ingelheim future offer beyond medicines hype field lots digital concepts centred patient theres idea addressed dr oliver reu huge selection sensor technologies team doctors biologists enabling patient measure instance blood pressure business managers blood sugar levels simply sometimes ongoing basis approaches involve blockchain order enable secure handling patient data dr reu boehringer ingelheim work practice technology primarily even considering technologies outside used financial sector context conventional medicine business dr reuss one hand work bitcoin course artificial together closely human intelligence huge topic dr reuss aim provide pharmaceuticals therapeutic areas patients comprehensive care define solutions identify new across fields weve primarily needs hand also pharmaceutical company primarily provided medicines thats say ways establish contacts outside boehringer consider overall challenges treat illness several years ingelheim innovative ideas often patients doctors healthcare however increasing focus come startups special partners system comes develop services technologies go known accelerators put us contact ment new medicines beyond putting patients startups position identify potential centre things offering gauge potential partnership solutions develop additional benefit early way able partners additionally incorporate entrepreneurial spirit knowledge regulatory affairs company context global presence absolutely necessary exciting boehringer ingelheim marketing new product venture fund recently received additional core competence utilise funding digital healthcare concepts competitive advantage l g aat general international signifi cance homelands scientific community grown considerably recent years china ranked second research usa turning terms number patents scientific publications international journals according forecasts trend set continue chinese government thus increasingly point investing resources promote science technology country graduated medicine tongji medical university wuhan standing sciences country good universi ties simply lacked resources finance research clear recent decades china become leading wanted achieve anything economic power country currently scientist would leave homeland case lots outstanding research involved chinese researchers time thousands talented people like help shape future left usa europe order continue research teach chinese government increased research spending per cent sustainable basis guest contribution ruiping xiao result situation today completely head institute molecular medicine different scientists peking university returning home china usa specialized cardio vascular disease national institute aging developed treat lots people asked left ments strengthen heart muscle usa return china eight years heart attack example ago worked basic research able continue research twenty years senior investigator field peking university national institute aging nih often time institute molecular medicine answer simple scientific also conducting basic research research historical turning consuming metabolic disorders looking point china wanted part consequences major diseases history home country expensive type diabetes compli progresses one leading cations like high blood pressure take decades search locations planet high cholesterol peking university invited disastrous impact whole body ever achieve become head new institute looking ways molecular medicine seized oppor treat complications marketable tunity accepted institute basic research often time research cardio metabolic consuming expensive take results diseases regenerative medicine decades ever achieve market fact become one leading able results without basic research institutions world past however medical breakthroughs years difficult team university h g e r f e e n l gathankfully opportunities pursue partners boehringer ingelheim costly necessary form peking university contract signing may beijing research scientist however foreground dr ruiping xiao might get stage need peking university dr clive support private sector wood head discovery research even best research thanks boehringer ingelheim fruitless fails reach people partnership strong industry partners come bringing strength zest near future thanks partnership boehringer develop results making boehringer ingelheim access ready market research results helps us imple ingelheim found partner ment practice boehringer ingelheim since may time boehringer access peking university coopera ingelheim supports peking university tion partner research beyond several ways company currently research results borders programme financing four postdoc positions boehringer ingelheim promotes highly helps us posts pipeline however promising research outside compa even important financial nys traditional therapeutic areas implement support wealth specialist exper strategic partnership primarily concerns tise able draw par regenerative medicine currently practice ticipants research beyond borders five projects investigating different programme boehringer ingelheim topics cell regeneration example extensive expertise heart pancreas however cancer research significantly joint research agenda also covers topics enriched research cancer diabetes research course career well gene therapy two researcher already worked projects also launched many different partners world l g aboehringer ingelheims discovery research strategy beyond borders n n vat n c r e e b u l n u r h r n e n e r g e r e n g h e e r g n g c e n c e boehringer ingelheim unifying scientific c ardiometabolic platforms eg diseases research beyond established research beyond immune modula diseases borders borders rbb team field tion fibrosis central nervous r egenerative discovery research team enabling technolo system medicine employees based biberach gies mmunology icrobiome germany ridgefield connecticut ncology gene therapy r espiratory boston massachusetts usa diseases beijing shanghai china kobe japan vienna austria locations teams boehringer ingelheims discovery research strategy based three pillars cooperation peking university supports goal harnessing emerging scientific developments activities scouts search international bundled third pillar research beyond borders see infobox right discovery research scientific community promising strategy helps boehringer ingelheim repeatedly originate innovations benefit patients company focuses external partnerships strengths approaches ideas actively establish contact researchers external research institutions industry always easy within research beyond borders universities many companies simply team lives works stand good research also china also familiar show apparent success decades european american ways working rbbs goal identify novel ultimately achieving major thanks knowledge worlds scientific approaches breakthrough overnight instead shes outstanding mediator technologies within beyond press quick results two cultures makes cross companys current therapeutic marketed profitably get border communication much easier rapid return investment aim future continue areas could future focus research work deepen expand cooperation areas examples regenerative conditions addition example plan establish medicine gene therapy cultural hurdles many companies five postdoc positions microbiome research unable handle properly finance part program meantime rbb concluded lead misunderstand ngs think important many make partnership difficult researchers work benefit partnerships precisely field basic society point china offering universities scientific insti research important able scientists exceptional opportunities tutes rbb also planning communicate properly unambig moment perhaps positions collaborations biotech uously boehringer ingelheim might enable us welcome companies startups understood part strategic returnees want miss partnership contact partner historic moment china h g e r f e e n l gai p r n f u h v e n q u e r e r c e n p l e e n h e e c n c u c h boehringer sohn ag co kg binger strae ingelheim germany telephone fax c n c corporate division communications public affairs email pressboehringeringelheimcom internet wwwboehringeringelheimcom u e b c h boehringer sohn ag co kg c n c e p e g n n l u mpm corporate communication solutions mainz wwwmpmde p h n l l u r n maskot plainpicture cover dieth schrder fotografie boehringer ingelheim michael alberstat masterfile istock shutterstock getty images istock alison romanczuk jovan vitanovski shutterstockcom august retrosesos alamy stock foto laura adani stocksy set design eva jauss photo michael breyer p r n e b neue sddeutsche verlagsdruckerei gmbh ulm c p r g h c h boehringer sohn ag co kg rights reserved part annual report may reproduced transmitted form means electronic photocopy without permission writing c h boehringer sohn ag co kg figures third parties used annual report based data avail able time financial statement drawn upwwwboehringeringelheimcom annualreportboehringeringelheimcombb oo ee hh rr ii nn gg ee rr ii nn gg ee hh ee ii mm n n u l r e p r value innovationf n ci l h gh l ig h ts um ar r ep r amounts millions eur unless otherwise indicated change net sales region europe americas summary asia australia africa report business human pharmaceuticals animal health biopharmaceuticals sales discontinued operations research development expenses personnel expenses average number employees operating income operating income net sales group profitloss net sales group equity return group equity investments tangible assets depreciation tangible assets top products human pharmaceuticals top products animal health net sales millions eur change net sales millions eur change spiriva nexgard na pradaxa frontline na trajenta jentadueto ingelvac ciroflex jardiance heartgard na newly aquired merial productso v e r v e w company shareholders perspective key aspects group management report consolidated financial statements product portfolio u r c p n improving health quality life patients goal researchdriven pharmaceutical company boehringer ingelheim focus diseases satisfactory treatment option exists date company therefore concentrates developing innova tive therapies extend patients lives animal health boehringer ingelheim stands advanced prevention familyowned since established boehringer ingelheim one pharmaceutical industrys top companies employees create value innovation daily three business areas human pharmaceuticals animal health biopharmaceuticals boehringer ingelheim achieved net sales almost billion euros rd expenditure exceeding three billion euros corresponded per cent net sales familyowned company boehringer ingelheim plans generations focuses longterm success rather shortterm profit company therefore aims organic growth resources simultaneous openness partnerships strategic alliances research everything boehringer ingelheim naturally adopts responsibility towards mankind environmentc n e n company shareholders perspective key aspects corporate bodies group management report information group report economic position risk report report expected developments consolidated financial statements overview major consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements independent auditors report product portfolio human pharmaceuticals respiratory diseases cardiovascular metabolic diseases oncology diseases central nervous system infectious diseases animal health livestock swine livestock cattle livestock poultry companion animals horse companion animals pets h e h r e h l e r p e r p e c v e christian boehringer chairman shareholders committee shareholders perspective gratitude satisfaction present boehringer ingelheims positive results annual report report proof reached patients human animal medicines made positive contribution disease progression thereby health past years structure positioning company undergone fundamental change even work quite finished already successfully completed fundamental tasks boehringer ingelheims primary objective remains maintain independence familyowned company time helping people animals innovative medicines convinced dedication commitment staff great value economic success clearly demonstrated come global focus initiative described path towards innovation growth future times change upheaval particular gives employees clear joint orientation motivation would like expressly thank every one successfully stepping challenges past year energy commitment working achieve company goals signed christian boehringer chairman shareholders committee f c u u r joachim hasenmaier michael schmelmer hubertus von baumbach andreas neumann core leitbild independent familyowned intend remain create value innovation customers powered people michel pairet allan hillgrove key aspects thank interest company pleased inform boehringer ingelheim progress past year one hand concerns annual report yearly financial statements hand would like invite find us accompanying agility report successful year boehringer ingelheim growth businesses would like highlight human pharmaceuticals business showed organic profitable distinctly abovemarket growth however looking sales figures rather see standing patients different medical histories us boehringer ingelheim motivated desire make important contribution health people animals generations boehringer ingelheim employees researching developing manufacturing innovative medicines positively change lives patients invest relatively large sums research new medicines future set goal particularly human pharmaceuticals business per cent innovations first patients relevant therapeutic approach mode action strategic decisions laid foundations new period successful growth boehringer ingelheim thus focused longterm success sectors digitisation means sustained change particularly databased industries like new bi x lab range initiatives facing challenge see opportunity achieved great deal past year success reflected trust c ustomers us would like thank would also like thank partners accompa nied supported us journey past year special thanks go employees stand achieved faced new challenges overcame dedication share passion making positive contribution innovation health people animals alike signed signed signed hubertus von baumbach joachim hasenmaier allan hillgrove signed signed signed andreas neumann michel pairet michael schmelmer c r p r e b e shareholders committee board managing directors christian boehringer hubertus von baumbach chairman shareholders committee chairman board managing directors christoph boehringer dr joachim hasenmaier corporate board division animal health erich von baumbach jr allan hillgrove isabel boehringer corporate board division human pharma dr mathias boehringer simone menne corporate board division finance prof dr dr andreas barner dr andreas neumann corporate board division human resources advisory board dr michel pairet corporate board division innovation egbert appel chairman advisory board michael schmelmer trustee martin hilti family trust corporate board division finance president hilti foundation kurt beck former ministerpresident dr nikolaus von bomhard former chairman board management mnchener rckversicherungsgesellschaft ag dr andreas kreimeyer former member board executive directors research executive director basf se jan rinnert chairman board management heraeus holding gmbh group management report boehringer ingelheim group management report consolidated financial statements product portfolio g r u p n g e e n r e p r information group report economic position risk report report expected developments group management report information group boehringer ingelheim information group companies group management report information group groups business model researchbased pharmaceutical company boehringer human pharmaceuticals form core boehringer ingelheim stood innovative medicines humans ingelheims activities medicines boehringer ingel animals years one heim long standard treatments respiratory worlds top pharmaceutical companies focus disorders cardiovascular diseases metabolic diseases familyowned company headquarters oncology diseases central nervous system ingelheim germany research development immunology production sale pharmaceuticals improving health quality life contributing great therapeutic benefit human medicine animal health three areas business human pharmaceuticals animal health biopharmaceuticals well discontinued net sales business eur million operations activities boehringer ingelheim gen erated net sales almost eur billion human pharmaceuticals employees worldwide start financial year exchange boehringer ingelheims consumer health care business animal health chc sanofis animal health business merial took place step represented successful completion strategic transaction began december exclusive negotiations underlines companys biopharmaceuticals consistent focus innovationoriented fields following successful completion transaction january boehringer ingelheims consumer health care business transferred sanofi return sales boehringer ingelheim received sanofis animal health division merial due changes within group consolidated compa discontinued operations nies numbers previous year comparable limited extent refer remarks within notes financial statements consolidated financial statements product portfolio net sales region eur million heartgard frontline successfully incorporated companys product portfolio established swine vaccine ingelvac c ircoflex used treat porcine circovirus type remains one significant products animal health terms net sales europe biopharmaceuticals business another important growth area boehringer ingelheim boehringer ingel asia heims biopharmaceutical activities comprise manu australia africa facture ownbrand marketable products americas aaa actilyse metalyse praxbind process devel opment manufacture new biological entities nbes biosimilars one worlds leading companies process development commercial companys biggest revenue contributor production biopharmaceuticals thirdparty indus spiriva used treat chronic obstruc trial customers tive pulmonary disease copd asthma moreover pradaxa used prevent strokes patients financial year boehringer ingelheim atrial fibrillation well prevention achieved majority sales americas treatment thromboembolic disorders trajenta europe regions region asia j ardiance remain growth path australia africa aaa strategic significance used treat type diabetes also made significant groups future growth making sales contributions boehringer ingelheims success fev three biggest markets usa japan germany newly introduced offers accounted sales last year people rare fatal respiratory disease idiopathic pulmonary fibrosis ipf new treatment option also research development rd achieved strong growth line mission statement boehringer ingelheims entrepreneurial goal research develop innovative business aim boehringer ingelheim continue medicines therapies treatment diseases drive forward innovative development yet satisfactory treatments available existing product portfolio organic growth aim times make major contribution cooperation external partners areas need treatment high occupy boehringer ingelheim operates global research network leading position major indication areas major facilities biberach hanover ingelheim human pharmaceuticals also within animal health germany ridgefield connecticut duluth georgia major emphasis development vaccines st joseph missouri usa well vienna antiparasites pharmaceuticals well new approaches austria lyon france therapies prevent detect treat chronic diseases effectively animal health business unit become second largest animal health business worldwide following boehringer ingelheim relies global research network merger boehringer ingelheims existing activities comprising facilities various countries around sanofis merial business products nexgard world well cooperation public research group management report information group boehringer ingelheim research development expenditure eur million net sales human pharmaceuticals expenditure eur million human pharmaceuticals net sales average number employees investments tangible assets without investments infrastructure eur million institutions academic institutions biotech com boehringer ingelheims rd activities basis panies research efforts supplemented companys sustainable success innovative capa various cooperation licence agreements field bility played key role groups positive business development projects technologies company development past years supplemented exter entered various agreements field oncol nal cooperation partnerships inhouse rd ogy focus highly innovative research approaches continue top priority future includes partnerships siamab therapeutics abexxa biologics well cooperation aca financial year employed average demic centres vanderbilt university university people rd facilities total almost eur california sarah cannon research institute billion invested rd new medicines partnerships gubra dicerna add compa corresponding groups net sales nys development portfolio area metabolic level expected diseases company also entered new partnerships alliances fields respiratory disorders human pharmaceuticals diseases central nervous system cns century committed improving lives people living respiratory diseases aforementioned partnerships key component scientific research field important boehringer ingelheims innovation strategy sup boehringer ingelheim year initiated plement highly comprehensive development portfo clinical trials announced new data help lio external partnerships thus boost innova increase therapeutic options patients tive capability rd also evidence doctors conditions focused chronic boehringer ingelheims solid successful coopera obstructive pulmonary disease copd idiopathic pulmo tion external innovation leaders nary fibrosis ipf systemic sclerosis interstitial lung disease sscild progressive fibrosing intersti july boehringer ingelheim established digital tial lung disease pfild laboratory bi x independent subsidiary serves platform innovation functions data new subanalyses tonado otemto trials science agile software development user experience spiolto tiotropiumolodaterol r espimat design cooperates exclusively boehringer ingel presented european respiratory society ers heims business areas develop goingtomarket health international congress september innovation human medicine animal health based new assessment copd patients according global initiative chronic obstructive lung disease gold guidelines subanalyses confirmed consolidated financial statements product portfolio tiotropiumolodaterol provides significant benefits offers opportunity patients would tiotropium monotherapy placebo terms otherwise eligible participate clinical trial symptom reduction quality life results prove copd patients benefit dual bronchodilation senscis trial safety efficacy nintedanib tiotropiumolodaterol early disease systemic sclerosis another example ongoing commitment improving lives patients living recently published gold report also recommends rare diseases end year recruitment dual bronchodilation longacting anticholinergic trial completed patients lama longacting betaagonist laba recruited largest global prospective clinical trial substance classes spiolto respimat firstline sscild date treatment option symptomatic copd patients gold groups bd boehringer ingelheim strongly committed oncology leading scientific discoveries patients obstructive respiratory diseases broad research development programme cancer cell important get medication deep directed agents immune oncology therapies lungs therefore inhaler plays important role combinations successfully advanced therapy r espimat innovative inhaler research programmes focused delivering firstinclass actively delivers unique mist meaning person treatments breakthrough potential needs take slow deep breath medication strengthen oncology portfolio company estab go deep lungs patient experience surveys lished series important partnerships strategic showed majority patients consider respimat collaborations many worlds leading academic easy use industry advocacy organisations well research driven startup companies commitment innovation results injourney trial investigating already resulted important treatments lung safety tolerability profile nintedanib combina cancer tion pirfenidone treating idiopathic pulmonary fibrosis ipf published september afatinib g iotrifgilotrif secondgeneration american journal respiratory critical care medi medicine treatment specific type nonsmall cine ajrccm results show combination cell lung cancer nsclc patients metastatic nsclc nintedanib pirfenidone resulted manageable squamous histology available patients since safety tolerability profile majority patients certain countries received approval giotrif china product become march enrolled first patient standard care many markets approved indica inbuild trial double blind randomized placebo tions additionally boehringer ingelheim initiated controlled trial evaluating efficacy safety giotag realworld study investigate treatment nintedanib weeks patients progressive sequence cancer cell directed therapies extend fibrosing interstitial lung disease pfild study chemotherapyfree treatment time patients investigates efficacy safety nintedanib study include patients started treatment range progressive fibrosing lung conditions afatinib part standard clinical practice followed idiopathic pulmonary fibrosis ipf approach thirdgeneration medicine realworld study builds enroll patients different fibrosing lung diseases comprehensive luxlung trial programme one trial exhibit progressive fibrosing behavior afatinib includes nine trials including direct head head randomized trials versus firstgeneration treatments group management report information group boehringer ingelheim boehringer ingelheims second cancer drug market initiated started recruitment second vargatef nintedanib treatment advanced quarter boehringer ingelheim eli lilly company nonsmall cell lung cancer nsclc approved und announced plans initiate additional new trial launched markets worldwide throughout empagliflozin treatment people chronic phase ii data lumemeso trial studied kidney disease trial also enrol participants effect nintedanib mesothelioma rare aggres without diabetes start sive cancer strongly associated asbestos con tact showed nintedanib combination stand trajenta linagliptin dpp inhibitor boehringer ard chemotherapy could prevent tumor continue ingelheims thirdbiggest product registered strong growing halved risk disease progression growth cardiovascular outcome studies results meaningful patients carmelina carolina continue planned currently treatment options available key results carmelina expected pub condition data phase iii trial nintedanib lished j ardiance trajenta mesothelioma expected available jointly marketed boehringer ingelheim eli lilly company boehringer ingelheims largest therapeutic area cardio vascular metabolic diseases achieved anticoagulation space saw publication strong growth boehringer ingelheim continue three important phase iii studies pradaxa invest area dabigatran etexilate praxbind idarucizumab highly recognised international congresses study company continue supplement regulatory also simultaneously published prestigious new product information jardiance empagliflozin england journal medicine march results sglt inhibitor worldwide order reflect data recircuit trial atrial fibrillation patients undergo risk cardiovascular disease resulting ing ablation presented american college landmark empareg outcome study number cardiology scientific sessions data showed signifi prescriptions increased continuously course cantly reduced major bleeding rates compared warfarin sales eur billion j ardiance ablation procedure study provided highly reached blockbuster status product relevant data electrophysiology specialists also frequently prescribed sglt inhibitor patients july final results reverse ad new brand prescriptions time j ardiance study praxbind idarucizumab presented oral antidiabetic drug market data international society thrombosis haemo label supporting use reduce risk cardio stasis biennial congress data showed p raxbind vascular death people type diabetes estab immediately reversed anticoagulant effect lished cardiovascular disease addition j ardiance pradaxa patients emergency situations sets apart inclass competition safety august results redual pci study atrial new data presented course show fibrillation patients following percutaneous coronary ing increased risk lowerlimb amputations lla intervention stent placement presented bone fractures development empagliflozin european society cardiology congress using p radaxa additional disease areas ongoing first quarter combination single platelet inhibitor led two emperor sister trials emperor highly significant reduction bleeding rate reduced emperor preserved aim inves compared standard care warfarin therapy tigate empagliflozin treatment people combination dual platelet inhibition addition chronic heart failure without diabetes number analyses based data routine clinical consolidated financial statements product portfolio practice published including new results biopharmaceuticals gloria aftm registry publications biopharmaceuticals brought significant changes confirmed established safety profile pradaxa treatment many diseases severely restrict patients lives since chronic diseases becoming hospitals already participating frequent health care systems exposed increasing angels initiative improved acute stroke care europe financial pressure relation treatment leading together european stroke introduction biosimilars improve sustaina organisation eso common goal optimise stroke bility health care systems allow patients treatment thus save lives benefit biologically produced medicines boehringer ingelheim developing biosimilars oncology animal health immunology goal providing therapy rd work field animal health boehringer options provide genuine value patients ingelheim traditionally concentrates innovative vac therapeutic areas cines protection livestock pets well pharmaceutical products treatment chronic cyltezo boehringer ingelheims biosimilar humira diseases core areas strengthened adalimumab approved usa companys acquisition merial begin eu treatment several chronic inflammatory ning supplemented third pillar autoimmune diseases adults children approval antiparasitics based comprehensive package data documents biosimilarity cyltezo humira facilities europe asia oceania north adalimumab according analytical pharmacological central south america focus research new nonclinical clinical data cyltezo available drugs development future therapeutic solu europe usa present boehringer ingelheim tions since many vaccines based local pathogens abbvie currently involved patent litigation pathogen variants imperative present usa key market regions local rd production facilities past year invested approximately bi boehringer ingelheims biosimilar candidate eur million new rd plants expansion avastin bevacizumab drug used treatment existing facilities investments demonstrate advanced stage cancers late phase clinical commitment strengthen animal health means development innovative preventive medicines intention sus tainably strengthen leading position field production human pharmaceuticals initiated clinical studies world task human pharmaceuticals production wide registered patents received reliable market launch products supply authorisations addition internal research patients using highquality pharmaceuticals development rd analyse external projects competitive costs boehringer ingelheim makes use products integrate portfolio global network comprising facilities contract appropriate obtaining approvals expanding manufacturers suppliers purpose able geographical distribution existing products react flexible manner continually evolving important aspects rd activities demands modern production network company launched strategy volume value late currently gradually rolled planned group management report information group boehringer ingelheim undergoing continuous development throughout animal health value chain subsequent acquisition merial boehringer ingelheim animal health operating network past year boehringer ingelheim operated plants facilities countries comprises sites manu countries plants manufacture pharmaceutical facturing vaccines five pharmaceuticals one products three produce important chemical active nutraceuticals industrial setup complemented substances boehringer ingelheim also one production contract manufacturers primarily north central facility medical products production facil america well europe defined new ities manufacture products particular relevance network strategy order balance internal exter group whose manufacturing technology requires nal production subsequently integration merial unique expertise production capacities focus core products full alignment busi appropriately supplemented strategic partnerships ness requirements investing globally foot contract manufacturers partners primarily focus mouth disease research capacities started manufacture products advanced stage consolidate relevant network china taizhou life cycle facility successfully obtained gmpcertificate past year important investments approved biopharmaceuticals particular ingelheim germany headquarters boehringer ingelheim pursues biopharmaceutical fornovo italy sant cugat spain yamagata activities facilities biberach germany vienna japan facilities ingelheim facility making austria fremont california usa shanghai china progress transformation goal focusing comprise manufacture ownbrand marketable initial market supply process future products actilyse etalyse p raxbind fornovo strengthened terms role ensuring manufacture new biological entities nbes routine supply chemical active ingredients biosimilars clinical testing one globally network sant cugat expand existing product port leading companies process development com folio include respimat technology investment mercial production biopharmaceuticals thirdparty yamagata intended meet needs japanese industrial customers top pharmaceutical patients longterm basis local level companies clients boehringer ingelheims biophar maceuticals business boehringer ingelheim covers volume value strategy intended opti entire biopharmaceutical value chain genetic mise underlying business processes well bringing development cell followed manufacturing greater focus production network boosting active substance filling finished pharmaceutical flexibility processes standardised product product launch global mar continuously optimised terms benefit ket supply business implemented way systems stepbystep throughout process chains endto comparison previous year saw overall end core elements active management increase almost full use capacity network products througho ut life cycle optimisation industrialscale production facilities boehringer ingel inventories worldwide implementation heims volume production meets continuously ris highp erformance global logistics distribution strategy ing demand actilyse particularly chinese market companys facility fremont california usa successfully approved fda ema authorities market production bio similar consolidated financial statements product portfolio cyltezo furthermore largescale plant technical support regular ehss audits biberach successfully completed registration processes boehringer ingelheims internal facilities prem two customer products submission ises suppliers contract manufacturers ensure com application approval authorities expansion pliance well international stand project new industrialscale biopharmaceutical produc ards eg pharmaceutical supply chain initiative tion facility boehringer ingelheims site vienna supplier code conduct applies relevant suppliers austria reached milestone foundations supplements programme status environ facility laid summer companys mental protection occupational safety continuously commercial facility shanghai china also success reviewed potential improvement identified fully put operation gmp hospital material basis addition company addresses important produced delivered studies china current social issues relevance boehringer countries scheduled ingelheim implementation sustainability goals important us consult closely stake occupational safety environmental holders within company outside protection make progress relation key issues taking protection employees facilities stand formulating related position papers striv environment well sustainable use natural ing achieve continuous improvements areas resources promotion environmental awareness sake company well sustainability major components companys mission state ment prime importance boehringer ingelheim boehringer ingelheim committed supporting uns compliance social environmental aspects sustainable development goals sdgs making firmly anchored corporate philosophy many contribution sustainable future rd un years ensure achieve sustainability climate change conference bonn conference future generations parties cop ehss representatives boehringer ingelheim participated many years company established groupwide binding standards terms environmental protection contribution towards reducing global co e emis health safety work internal guidelines reflect sions set goal reducing respective countryspecific requirements many cases entire co emissions compared go far beyond standards prescribed law values particular follow international standards guid ance documents work close cooperation health safety employees high priority relevant associations within boehringer ingelheim cor boehringer ingelheim reflected interna porate department environment health safety sus tional safety standards safety culture tainability ehss responsible strategic focus practise rollout groupwide safe ini tiative aims reduce number work boehringer ingelheim characterised place accidents continued successful workshops integration sanofis animal health division merial held focus behaviourbased safety group ensure compliance ehss duty care environmental risk assessments imple employee reporting mented new facilities integration audits boehringer ingelheim employed people initiated standards aligned processes har worldwide represents increase monised group management report information group boehringer ingelheim report economic position previous year boehringer ingelheim increased num professionals company backdrop demo ber staff regions graphic change young professionals started careers boehringer ingelheim germany average number employees region different scientific technical commercial americas fields young people enrolled europe training programme asiaaustraliaafrica aaa one companys aims strengthen appeal boehringer ingelheim top employer current major success factor positive growth group future employees boehringer ingelheim motivated reliable staff accordingly par recipient various awards efforts area ticularly committed actively developing supporting received top marks auditors employees order best prepared chal international independent top employers institute lenges ahead part comprehensive training relation key areas staff planning performance system set great store acquisition management career succession planning well technical expertise also promoting social skills compensation benefits received distinction facilities germany well facilities integration various experiences cultural back china taiwan brazil russia spain poland grounds personalities boehringer ingelheim creates number countries awarded rating openness different approaches opinions living unprecedented evidence strong appeal corporate vision value innovation development opportunities company global company important us diver employees potential recruits sity markets reflected workforce creating working environment embraces diversity differ social responsibility ences one pillars corporate culture taking social responsibility also important aspect boehringer ingelheim contributing factor corporate culture commitment wellbeing companys success patients employees families focus range projects addition support people need addition competitive salaries boehringer ingelheim various initiatives countries regions offers benefits employees include active company companys activities range company pension plans flexible homebased also focus protecting maintaining environment work options numerous healthrelated benefits significant segment corporate strategy part previous years boehringer ingelheim continues talent management departments remit ensure assist providing support integration people employability staff promote wide range oppor fled home country migrants tunities innovation work motivate employees crisis regions pursues broad range measures nurture talents develop individuals area boehringer ingelheim employees germany conducting integration workshops state centre vocational training always major importance asylum seekers ingelheim addition since mid boehringer ingelheim part understanding company pursued partnership deutsche social responsibility company offers career opportunities universittsstiftung partnership boehringer great number young people time ingelheim sponsors welcome scholarship pro also tie talented wellqualified workforce young gramme supports students crisis regions consolidated financial statements product portfolio company also helps candidates crisis regions lecturers learn socially entrepreneurial areas people fleeing join company offer thinking practical activities development ing apprenticeships opportunity complete social entrepreneurship projects introductory training year internship boehringer ingelheim values respects employees major pillar social commitment making differences actively promotes diverse cooperative health mmh initiative since start open working environment conscious developed social entrepreneurship movement fact diversity markets customers within company externally socially com reflected workforce us diversity makes mitted sustainable activities limited individ right mix inclusion brings ual projects relating various regions issues instead best results mix therefore focus encour initiative focuses connecting local inter aging inclusive environment kind diver national partners different sectors networking sity thrive boehringer ingelheim participated across traditional visible invisible borders cen th german diversity day motto diversity tral element successful social movement order companies two largest german facilities ingel identify promote implement innovative solutions heim biberach official member farreaching complex challenges healthcare diversity charter since early sector cocreation bridge social com mercial entrepreneurship brings together social entrepre neurs nonprofit organisations health care report economic sector boehringer ingelheim employees position resources date within mmh network boehringer ingelheim ashoka one worlds largest non profit organisations together helped macroeconomic environment social entrepreneurs reach million people growth almost global economy area healthcare robust form neither usas increasing protec tionism brexit vote sources internally mmh featured boehringer ingelheims economic uncertainty significant negative impact hr development activities years markets growth volume world trade changed understanding emerging markets initi paced global gross domestic product growth first ative supported executive residence eir time since europes economic recovery continued mmh insight india staff development programmes larger countries achieved stronger growth part network partnerships nonprofit organi rates past year pre vious year nonethe sations social enterprises healthcare sector less eurozone continued burdened huge programmes give young professionals opportu structural weaknesses member states picture nity support participants project facilities emerging economies mixed growth turkey certain period time jointly develop projects declined significantly due political conflicts improving health means understanding peo country brazil russia back track ples environment everyday challenges growth spent past years recession par offering solutions needed health aware ticularly account decline crude oil prices ness affordability accessibility health services acceptance play key role mmh plays role growth also picked japan buoyed expansionary university sector goal helping students fiscal monetary policies increasing exports group management report report economic position boehringer ingelheim pinned investments rising wages private households apparent sectors however overall terms declining unemployment stimulated consumer economic upturn continue price adjusted gross spending willingness invest usa mone domestic product growth thus expected exports tary environment remained favourable despite three maintain clear upward trend driven improved interest rate hikes implemented american central economic outlook eurozone rest world bank level inflation moderate additional budget costs likely resolved following formation new german government growth expected almost world regions global growth level predicted risks sur consumer prices increased rapidly crude oil rounding growth europe continue include possi food prices picked considerably prices ble consequences brexit well negative effects increased past year thus close resulting intensifying international competition target inflation rate european central bank field taxation due americas tax reform ecb euro currency area whole despite slight usa likely additional stimulating effect overutilisation tensions areas economy economy stabilisation oil prices encour sign overheating germany age fresh investments energy sector addition euro major currencies china high level growth expected boehringer ingelheim group us dollar usd even slightly weaker previous japanese yen jpy us dollar fluctuated year larger emerging economies likely pick usdeur january usdeur growth due stabilising commodity prices december reached low usdeur sep tember japanese yen remained volatile germany economy benefiting broad euro usual end year euro picked based upward trend reflected lowest japanese yen rate jpyeur unemployment rate years lively consumer reached low jpyeur midapril demand among private households coun tries european central banks low interest rate pol global pharmaceuticals market registered growth icy stimulated demand construction investments financial year trend driven influx refugees triggered growth rising demand industrialised countries cancer level government consumption spending adjusted medicines products treatment autoimmune low number working days countrys gross diseases antidiabetic medicines due ageing domestic product increased government finances population industrialised countries industrys registered significant surpluses despite expansionary growth remained stable albeit slightly weaker spending policy solid economy declining interest previous years development also related struc payments reduced ratio debt tural problems eurozone emerging countries countrys gross domestic product leads decelerating growth demands general increasing supply constraints labour course business market heavy use capacities somewhat longterm sustainably successful development forms limit opportunities growth rise level basis securing companys independence employment set drop due low level long term combined stable earnings sound immigration process demographic change financing core boehringer ingelheims aggravating scarcity skilled workers already consolidated financial statements product portfolio strategic focus previous years based approach overall sales growth exceeded expectations supported principles good results clinical trials able place promising new products market successfully year characterised significant changes push ahead wellestablished products boehringer ingelheim changes also hand experiencing increasingly difficult market represented important steps companys future situation constantly challenging market access completion exchange consumer health care growing price pressure key markets overall business sanofis animal health business merial company asserted well despite difficult con turn year one biggest changes ditions laid foundations future growth past years transaction significantly improve market position field animal health boehringer ingelheim recorded operating income establish us one largest global players eur million corresponding return sales segment percentage points previous years return sales operating income includes boehringer ingelheim recorded net sales eur mil significant positive eur million negative lion financial year corresponds eur million extraordinary effects mainly increase compared previous years figure associated exchange business areas sanofi eur million exchange rate developments despite negative impact amounting eur mil foreign exchange markets associated exchange lion operating income increased eur million rate effects slight impact currency adjusted absolute terms result positive sales growth boehringer ingelheims growth rate stood financial income negatively affected interest sales eur million americas region effects pensions similar liabilities hold represents around total sales remains ing income reduced due impairmennt related biggest market boehringer ingelheim strong company income taxes therefore slightly increase sales previous year mainly higher previous year due purchase merial europe region like wise registered strong sales growth reached key figures eur million change eur million accordingly previous year net sales groups sales achieved region operating income asia australia africa aaa region registered return net sales growth currencyadjusted sales increased boehringer ingelheim realised revenues eur mil lion region corresponding share around tax expenses also influenced significant extra groups total revenues ordinary effects tax expenses current period include tax expenditure due disposal companys consumer health care business moreover usa net sales region currency eur million change adjusted tax reform approved december americas tax cuts jobs act required revaluation europe deferred tax assets liabilities based corpo asiaaustraliaafrica rate income tax rate enacted law balance aaa sheet date future financial years likewise significant negative impact tax expenses group management report report economic position boehringer ingelheim overall boehringer ingelheim recorded positive ingelheim able assert well difficult development operating business environment laid foundations fur financial year despite negative onetime effects related ther growth integration merial animal health business sale consumer health care business due previous years piriva used treat chronic far highest tax payments companys obstructive pulmonary disease copd history effects connected us tax reform biggest contributor sales achieved boehringer ingelheim group ended year revenues eur million reporting period group loss eur million group profit thus slightly previous years level eur million eur mil lion europe particular sales spiriva declined significantly due increased earnings position level generic competition account loss past financial year boehringer ingelheims business relevant patent activities divided human pharmaceuticals ani mal health biopharmaceuticals consumer health second biggest sales contributor boehringer care business sold sanofi january ingelheim anticoagulant pradaxa recorded sales reported discontinued operations eur million corresponds increase still includes production services level yet completed within scope transferring business sanofi eur million medicine j ardiance used treatment type diabetes achieved sales net sales businesses currency excess one billion euros first time eur million change adjusted human pharmaceuticals animal health net sales eur million change biopharmaceuticals spiriva sales pradaxa discontinued operations trajenta jentadueto jardiance human pharmaceuticals regard regional distribution sales usa around total revenue human pharmaceuti share far largest cals main pillar boehringer ingelheims business market boehringer ingelheim generated sales activities revenues amounted eur mil eur million corresponds increase lion equivalent change cur compared previous year currency rency adjusted compared previous year adjusted increase volume price driven positive sales growth trend resulted particular successful placement innovative products well secondbiggest market europe accounted solid market position established medicines revenues eur million sales decreased emerging markets us market key growth compared eur million exchange drivers continuing experience increasing rate effects significant influence price pressure however particularly established medi sales trend europe price pressure piriva cines many major markets overall boehringer declining sales established brands impact consolidated financial statements product portfolio biopharmaceuticals net sales region eur million change sales biopharmaceutical contract manufac usa turing amounted eur million represents europe growth compared previous year emerging markets japan presentation expenditure income cost materials higher previous emerging markets sales increased year eur million coming eur mil eur million currency adjusted sales lion represented cost materials ratio previous year amounted eur million due personnel expenses amounted eur million expiry patent icardis sales japan corresponding personnel cost ratio decreased eur million increased thus percentage points lower previous year level sales products unable compensate effect line expectations depreciation amortisation recorded increase eur million eur million animal health operating expenses rose compared pre revenues products animal health business vious year coming eur million among increased eur million past financial year items cost category includes commission licence due acquisition merials activities corresponding payments dependent sales increase previous year currency adjusted operating income higher previous year eur million coming eur million net sales eur million change influenced significant positive considera nexgard na bly higher negative extraordinary factors onetime frontline na effects particularly related exchange business ingelvac circoflex areas sanofi reversal provisions adjusted heartgard na extra ordinary effects operating income considerably higher previous year groups regions benefited sales exceeded expectations growth four bestselling products include three products merial group nexgard frontline reporting period financial income amounted heartgard eur million eur million compared year mainly due interest effects net sales region resulting pensions similar obligations holding eur million change income also decreased particular due impairment usa loss related company investment europe metasia despite decrease financial income holding latin america inome income taxes amounted eur mil lion thus eur million higher product ingelvac c ircoflex achieved previous year tax expenses influenced sig sales growth sales eur million achieved nificant extraordinary effects tax expenses cur growth rate compared previous year rent period include tax expenditure due disposal group management report report economic position boehringer ingelheim risk report companys consumer health care business approved relevant committee standardised usa tax reform approved decem process ber tax cuts jobs act required revaluation deferred tax assets liabilities based investments particular importance boehringer corporate income tax rate enacted law ingelheim strategic point view continuous balance sheet date future financial years like investment requirement longterm development wise significant negative impact tax expenses company forms basis profitable growth business activities must noted regard provisions german commercial law shareholders personal taxes total eur million invested tangible arising group business activities may recog intangible assets year review nised tax expenses instead taxes presented part withdrawals group equity taking april groundbreaking ceremony took place extraordinary effect account actual tax ratio expansion biopharmaceutical production vienna markedly higher figure shown profit austria investment volume eur mil loss statement lion including infrastructure measures biggest single investment boehringer ingelheims company overall despite positive business development tory new jobs thus created significant increase operating income significant facility decades boehringer ingelheim group ended year con solidated loss eur million consolidated new biopharmaceutical production facility also profit eur million due far highest tax opened shanghai china new jobs payments companys history effects con created initial investment phase nected us tax reform eur million already invested project facility first date bio financial position pharmaceutical cell culture production facility launched boehringer ingelheims financial management instruments leading international biopharmaceutical manufac methods aimed securing liquidity minimising turer china global network biopharmaceu financial risks optimising cost capital tical production facilities biberach germany vienna appropriate capital structure financial activities austria fremont california usa shanghai therefore geared towards supporting business strategy china boehringer ingelheims contract manufacturing business boehringer ingelheim bioxcellence well global company exchange rate volatility sig placed supply innovative products reliably meet nificant impact boehringer ingelheims financial per strong rise demand biopharmaceutical formance importance us business industry china also worldwide associated supply relationships mean exchange rate development us dollar constitutes greatest cash flow operating activities amounted individual risk within framework groupwide eur million despite significantly financial reporting foreign exchange risk calculated higher operating income represented slight decline generally hedged derivative financial eur million contrast provision instruments nature scope measures releases operating income previous year set group guidelines regularly discussed included increase provisions cash flow invest ments eur million mainly impacted consolidated financial statements product portfolio cash settlement exchange business areas provisions higher pre sanofi tax payments resulting sale vious year amounted eur million accounts consumer health care business cash outflow payable loans also increased past year financing activities eur million mainly includes totalling eur million repayment financial liabilties merial companies previous holding company sanofi overall status already shown financial position remains taking consideration exchange effects changes resoundingly positive balance sheet within group consolidated companies led respective balance sheet ratios sum boehringer decrease boehringer ingelheim groups financial ingelheims net assets financial earnings position funds eur million eur million confirm credentials soundly financed profitable company net assets financial year boehringer ingelheims total risk report assets amounted eur million increase eur million compared previous year due acquisition merial tangible risk opportunity management intangible assets amounted eur million aim risk management system implemented boehringer ingelheim identify businessspecific end year financial investments amounted risks particular risks jeopardise continued eur million corresponds decrease existence company early possible assess eur million previous years value inventories reduce reasonable level means showed growth eur million trade suitable measures receivables rose eur million eur million liquid funds including securities within current assessing risks context holistic risk assets stood eur million previous year management also endeavour take account eur million resulting opportunities opportunity management based strategies objectives company view aforementioned changes group equity individual businesses operating business units amounted eur million thus covers value integral part groupwide planning manage groups tangible intangible assets addition ment systems responsible businesses equity pension provisions longterm accounts functions bear direct responsibility early sys payable loans also available group tematic identification analysis use opportunities long term total three items amounted boehringer ingelheim researchdriven inno eur million representing share vative pharmaceutical company current research total assets consequently longterm dispos development activities naturally considered relevant able capital covers intangible tangible assets opportunity relevant projects already illustrated well trade receivables research development chapter difference capital consolidation increased persons responsible key businesses func eur million eur million exclusively tions included process calculating assess driven exchange consumer health care busi ing risks groupwide risk information system ness sanofis animal health business ensures identified risks analysed assessed carefully following appropriate classification group management report risk report boehringer ingelheim various categories adequate countermeasures initi credit countryspecific risks ated implementation consistently monitored boehringer ingelheim exposed various credit countryspecific risks result international busi year review internal auditing performed ness activities portfolio trade accounts targeted routine audits well extraordinary audits receivable trade accounts payable identi around world addition compliance legal fied extraordinary risks group beyond requirements internal group guidelines main usual level sector applies possible focal points functionality systems effec default risks receivables largely hedged tiveness internal controls prevention loss economic political risks continue assets efficiency structures processes carefully track credit countryspecific risks corresponding adjustments optimisations initi position respond negative changes timely manner ated necessary risks therefore regarded concrete individual risks financial investment shareholding risks important risks boehringer ingelheim group pursues defensive investment strategy exposed broken following specific cate management financial assets reflected gories financial risks legal risks production environ orientation portfolio focused european mental risks personnel risks industryspecific risks economic monetary union emu government bonds top credit ratings shortterm investments risks identified concrete selected banks results concrete thus appear controllable means specific manage controllable risk major part financial invest ment procedures term abstract used case ments net book value strategic invest risks completely controlled even ments related companies affected market means targeted management procedures regardless business circumstances leads higher vola probability occurrence tility fair market value specific risks covered respective impairments consolidated financial risks financial statements relevant financial risks broken follows currency risks credit countryspecific risks legal risks well financial investment shareholding risks business activities group exposed legal risks distinction made regulatory liability currency risks patent protection risks global orientation business activities results currency risks due exchange rate volatility particularly regulatory risks regard us dollar japanese yen group boehringer ingelheim exposed risks arising legal monitors quantifies risks regular intervals disputes proceedings well official investigations making predictable future business means legal administrative decisions ongoing future relevant hedging strategies appropriate financial proceedings predicted regard resultant instruments forward exchange contracts risks abstract resultant risks subsequently designated con crete thus controllable liability risks marketing sale pharmaceuticals exposed potential product liability risk boehringer ingelheim consolidated financial statements product portfolio currently product liability insurance covering com risks areas environment health safety panys risk profile absolutely guarantee sustainability ehss preemptively minimised ever insurance coverage maintained ensuring global compliance high safety stand reasonable cost acceptable conditions suf ards appropriate emergency plans drawn ficient protect boehringer ingelheim claim possible incidents kind practised loss potential claims losses case subjected comprehensive quality testing regular foreseeable product liability insurance intervals result measures risks parts cover specific liability risk remaining classed concrete risk exposure covered provision personnel risks furthermore product liability claims could tie sub boehringer ingelheim companies exposed stantial financial resources management capacity demographic change resultant risk detrimental companys image event affected lack appropriately qualified personnel market considers product unsafe ineffec potential risk substantial impact tive result unexpected side effects regard companys business activities therefore risk abstract included longterm planning process many years gained strategic significance result patent protection risks boehringer ingelheim counters risk means protection innovations trademark brand comprehensive personnel concept regardless patent rights particular importance boehringer ethnic background gender religion offer com ingelheim research company commercial pro pany employees development opportunities based tective rights increasingly target attacks vocational skills social expertise personal aptitudes breaches taken necessary precautions allow willingness take responsibility accordance us detect threats early stage commencing needs company view counter appropriate countermeasures defend legal position measures described risk regarded concrete using legal means available us risks regarded concrete industryspecific risks boehringer ingelheim exposed business risks spe production environmental risks cific pharmaceutical industry risks quality management system compliance processes materialised past financial year increasing continuously optimised close cooperation significance result impact boehringer relevant authorities order ensure compliance ingelheim continue classed abstract cgmp standards current good manufacturing practices risks area continue high significance addition loss exclusivity products estab group classified abstract lished market risks associated devel opment registration new products risks order guarantee supply products increasingly include changing restrictive requirements market implemented measures guarantee relating pricing reimbursement many sales reliable highquality supplies internal exter markets frequently prices pharmaceutical products nal customers addition supplier management subject state monitoring regulation procurement side also involves building internal also price pressure cheaper generic drugs standby capacities result see risk concrete caused state reimbursement systems boehringer group management report risk report boehringer ingelheim report expected developments ingelheim therefore keeping close eye various growth innovation continue changes sales markets takes appropriate meas successful market future regard ures response current developments many changes healthcare systems increasing price pressure particularly wellestablished medicines overall statement risk situation many major markets regard increasing current perspective aware risks challenges market access new products alone conjunction risks could lead expect low growth impetus pharmaceutical indus lasting impairment companys assets financial try coming year boehringer ingelheim asserted earnings position could jeopardise continued well despite difficult conditions existence boehringer ingelheim laid foundations growth presume revenue continue grow report expected slightly comparable basis ie without discontinued developments operations research development expenses remained high year review intense line strategy drive growth pro challenging time boehringer ingelheim mote new products future primarily products laid foundations sustainable development research development facilities longterm growth company several major invest area care close investigation decisions therapeutic benefit associated prospects success comprehensive portfolio prospective consistent focus business innovation products promising study outcomes along oriented fields attested strategic exchange newly approved products significant sales potential sanofis animal health business merial boehringer justifies high level investment research ingelheims consumer health care business contract development envisage slight increase exchange signed june trans investments research development new action successfully closed january pharmaceuticals transaction improve competitiveness animal health business industrys important addition patent expiry attacks patents growth markets enable us offer customers major challenges facing researchdriven pharmaceu worldwide even innovation added value tical industry increasing amount investment high level pooling complementary product rd well bigger hurdles increased costs associ portfolios merial boehringer ingelheim exist ated product approvals context also ing technology platforms vaccines anti parasitic increasing cost pressure healthcare systems well pharmaceutical speciality products particularly emphasised leading decreasing willing ness adequately recognise large amounts invested increasingly difficult market environment increased development new medicines result unpredictability business posed major challenges significant price pressure major markets pre entire pharmaceutical industry continue scription medicines conjunction longer planning require significant attention boehringer ingelheim development cycles new products makes regard competitiveness even business less predictable requires us recognise important therefore retain scope seize opportunities quickly one hand sub consolidated financial statements product portfolio jecting costs strategies continual monitoring adjustments hand end launched initiatives past years accelerate reaction changes reduce organisational complexities well lower cost base order create potential investments secure com panys longterm success difficult market envi ronment one hand potential resulting measures introduced well promis ing new product launches hand plan see operating income comparable basis slightly last years level familyowned company boehringer ingelheims pri mary aim maintain firms independence com petitiveness longterm sustainable organic growth still takes precedence shortterm profit tar gets confident achieve ambitious targets thanks great innovative strength based comprehensive portfolio prospective products global presence support highly qualified motivated employees current product launches expansions emerging markets boost growth areas business stand vision value innovation hence research develop innovative products offer high medical benefits bring market result efforts provide new medicines enable doctors treat patients novel therapies effectively consolidated financial statements boehringer ingelheim consolidated financial statements product portfolio c n l e f n n c l e e n overview major consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements independent auditors report overview major consolidated companies boehringer ingelheim overview major consolidated companies c h boehringer sohn ag co kg boehringer ingelheim boehringer ingelheim boehringer ingelheim vetmedica gmbh europe gmbh international gmbh australia r germany p r austria p r austria r boehringer ingelheim animal health boehringer ingelheim boehringer ingelheim rcv forschungsinstitut fr molekulare australia pty ltd north ryde pharma gmbh co kg gmbh co kg vienna pathologie gesellschaft mbh ingelheim vienna boehringer ingelheim brazil p r boehringer ingelheim gmbh pharma gesmbh vienna ingelheim belgium merial saude animal ltda boehringer ingelheim paulo microparts gmbh dortmund czech republic scs boehringer ingelheim comm v brussels boehringer ingelheim boehringer ingelheim spol ro china p r biopharmaceuticals gmbh prague ingelheim china p merial animal health co ltd boehringer ingelheim veterinary nanchang finland boehringer ingelheim research center gmbh co kg international trading shanghai hanover boehringer ingelheim co ltd shanghai denmark p r finland ky espoo merial norden hoersholm philippines norway boehringer ingelheim france p r boehringer ingelheim phil inc manila norway ks asker merial sas lyon usa p r poland italy p merial inc duluth georgia boehringer ingelheim sp z oo merial italia spa milano warsaw merial select inc gainesville georgia japan r boehringer ingelheim animal health japan co ltd tokyo puerto rico p merial barceloneta lcc barceloneta united kingdom p merial animal health ltd harlow distribution p production r research development sole personally liable managing shareholder boehringer ag product portfolio c h boehringer sohn grundstcksverwaltung gmbh co kg boehringer ingelheim auslandsbeteiligungs gmbh argentina r france p netherlands p taiwan boehringer ingelheim sa boehringer ingelheim boehringer ingelheim bv alkmaar boehringer ingelheim buenos aires france sas paris taiwan ltd taipeh boehringer ingelheim animal health operations bv alkmaar australia greece p thailand boehringer ingelheim pty ltd boehringer ingelheim ellas ae new zealand boehringer ingelheim north ryde athens thai ltd bangkok boehringer ingelheim nz ltd auckland brazil p india turkey boehringer ingelheim brasil boehringer ingelheim portugal boehringer ingelheim ilac quimica e farmaceutica ltda india private ltd mumbai ticaret istanbul paulo boehringer ingelheim lda lisbon solana agro pecuaria ltda unilfarma lda lisbon indonesia p united kingdom arapongas pt boehringer ingelheim boehringer ingelheim ltd singapore indonesia jakarta bracknell canada boehringer ingelheim boehringer ingelheim singapore pte ltd singapore ireland usa p r canada ltd burlington boehringer ingelheim boehringer ingelheim corp south africa ireland limited dublin ridgefield connecticut chile boehringer ingelheim pty ltd boehringer ingelheim boehringer ingelheim ltda randburg pharmaceuticals inc italy p r santiago de chile ingelheim pharmaceuticals pty ridgefield connecticut boehringer ingelheim ltd randburg boehringer ingelheim italia spa reggello usa corporation china p bidachem spa ridgefield connecticut south korea boehringer ingelheim shanghai fornovo giovanni boehringer ingelheim pharmaceuticals co ltd shanghai boehringer ingelheim korea ltd vetmedica inc boehringer ingelheim china seoul st joseph missouri japan p r investment co ltd shanghai boehringer ingelheim boehringer ingelheim vetmedica nippon boehringer ingelheim spain p fremont inc china co ltd shanghai co ltd tokyo fremont california boehringer ingelheim animal health boehringer ingelheim boehringer ingelheim operations china co ltd taizhou vetmedica japan co ltd espaa sa barcelona tokyo boehringer ingelheim sa barcelona boehringer ingelheim colombia p seiyaku co ltd yamagata europharma sa barcelona boehringer ingelheim sa boehringer ingelheim laboratorios fher sa barcelona bogot japan inc tokyo sweden denmark p mexico p r boehringer ingelheim ab stockholm boehringer ingelheim boehringer ingelheim danmark copenhagen promeco sa de cv switzerland mexico city boehringer ingelheim vetmedica boehringer ingelheim ecuador sa de cv guadalajara schweiz gmbh basel boehringer ingelheim del ecuador cia ltda quito consolidated financial statements consolidated balance sheet boehringer ingelheim consolidated profit loss statement c h boehringer sohn ag co kg ingelheim consolidated balance sheet assets millions eur notes intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets securities cash cash equivalents current assets prepaid expenses deferred taxes exceeding amount plan assets total assets liabilities equity millions eur notes shareholders capital group reserves balance sheet currency conversion difference equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions accounts payable loans liabilities deferred charges deferred taxes total liabilities equity explanations see relevant section notes consolidated financial statements product portfolio c h boehringer sohn ag co kg ingelheim consolidated profit loss statement millions eur notes net sales changes finished goods work process work capitalised operating income total revenues cost materials personnel expenses amortisation intangible assets depreciation tangible assets operating expenses operating income financial income holding income income taxes income taxes income taxes net lossincome noncontrolling interests group lossprofit explanations see relevant section notes consolidated financial statements due legal requirements disclosure shareholders personal taxes arising consolidated business activities tax expenses allowed taxes shown withdrawals group reserves consolidated financial statements cash flow statement boehringer ingelheim tatement changes group equity c h boehringer sohn ag co kg ingelheim cash flow statement millions eur income taxes including thirdparty share amortisation intangible assets depreciation tangible assets change provisions pensions change provisions noncash income expenses gainloss disposals fixed assets change inventories change accounts receivable assets related investing financing activities change trade accounts payable liabilities related investing financing activities interest incomeinterest expenses net income investments incomeexpenses extraordinary magnitude significance income taxes cash receipts extraordinary magnitude significance income taxes paid cash flow operating activities investments intangible assets investments tangible assets investments noncurrent financial assets investments consolidated companies proceeds disposals intangible assets proceeds disposals tangible assets proceeds disposals noncurrent financial assets cash receipts extraordinary magnitude significance interest received income dividends income taxes paid due sale businesses cash flow investing activities product portfolio c h boehringer sohn ag co kg ingelheim cash flow statement millions eur cash receipts grants interest paid cash payment owners parent entity cash repayments loans cash flow financing activities change liquid funds cash relevant transactions changes liquid funds due change consolidated companies changes liquid funds due exchange rate movements financial funds financial funds excl fixedasset securities liquid funds securities within fixed current assets source funds use funds statement changes group equity balance sheet equity attri currency butable non shareholders group conversion parent controlling millions eur capital reserves difference company interests group equity balance withdrawals net income changes currency effects balance withdrawals net loss changes consolidated companies currency effects balance shareholders capital consists equity c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg shareholders capital consists limited partners capital contribution shareholders personal taxes arising consolidated business activities shown withdrawals group reserves december negative capital account one limited partner amount eur million previous year eur million shown net item within group reserves liability limited partner reinstated amount eur consolidated financial statements notes boehringer ingelheim c h boehringer sohn ag co kg ingelheim notes consolidated financial statements principles methods general principles consolidated financial statements boehringer ingelheim financial year prepared accordance section german commercial code hgb line legal requirements prepare consolidated financial statements section et seq hgb accordance section hgb consolidated financial statements consist consolidated balance sheet consolidated profit loss statement notes consolidated financial statements cash flow statement statement changes equity consolidated financial statements prepared euros accordance section conjunction section hgb improve clarity transparency consolidated financial statements individual items consolidated balance sheet consolidated profit loss statement combined items presented explained separately notes additional disclosures required individual items also found notes registry information parent company registered name c h boehringer sohn ag co kg headquarters ingelheim commercial register mainz district court number hra information companies included consolidation parent company boehringer ingelheim group c h boehringer sohn ag co kg ingelheim boehringer ag ingelheim sole personally liable managing shareholder company besides c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg whose general partner controlled c h boehringer sohn ag co kg boehringer ingelheim group consists total affiliated companies germany abroad addition c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg companies c h boehringer sohn ag co kg directly indirectly holds majority voting rights included consolidated financial statements full consoli dation rules product portfolio accordance section hgb companies included consolidation reporting year individually collectively insignificant groups net assets financial earnings position total amount sales equity net income year companies included consolidation accounts less aggregated group financial statements totals two affiliated companies ongoing restrictions control due terms articles association companies also consolidated accordance section hgb total number affiliated companies increased compared previous year companies acquired exchange business areas boehringer ingelheim sanofi completed january two companies pharmaton ssp co ltd sold exchange business areas boehringer ingelheim sanofi seven companies founded two companies lost separate legal identity merger boehringer ingelheim animal health gmbh merial gmbh latter acquired exchange business areas boehringer ingel heim sanofi one unconsolidated affiliate company liquidated following subsidiaries exempted reporting disclosure obligations section hgb boehringer ingelheim gmbh ingelheim boehringer ingelheim europe gmbh ingelheim boehringer ingelheim secura versicherungsvermittlungs gmbh ingelheim boehringer ingelheim grundstcksgesellschaft mbh ingelheim boehringer ingelheim finanzierungs gmbh ingelheim boehringer ingelheim rd beteiligungs gmbh ingelheim boehringer ingelheim venture fund gmbh ingelheim boehringer ingelheim invest gmbh ingelheim following subsidiary companies exempt duty prepare disclose annual financial statements management reports accordance section b hgb c h boehringer sohn ag co kg ingelheim c h boehringer sohn grundstcksverwaltung gmbh co kg ingelheim boehringer ingelheim pharma gmbh co kg ingelheim c h boehringer sohn selbstmedikation gmbh co kg biberach boehringer ingelheim veterinary research center gmbh co kg hanover two joint ventures acquired exchange business areas boehringer ingelheim sanofi included consolidated statements either using proportionate method equity method since material consolidated financial statements notes boehringer ingelheim accordance section hgb associated companies also included using equity method due lack significance consolidation methods inventories fixed assets receivables liabilities income expense items transactions companies included consolidation eliminated part debt consolidation procedures accordance section hgb procedures eliminate intercompany profits accordance section hgb income expenses consolidation procedures accordance section hgb revaluation method applied including subsidiary companies consolidation first time accordance section hgb companies included consolidation first time date company became subsidiary carrying amount shares held parent company offset corresponding equity subsidiary equity carried amount fair value assets liabilities prepaid expenses deferred income special reserves included consolidated financial statements time consolidation remaining positive balance recorded goodwill remaining negative balance recorded difference capital consolidation currency translation assets liabilities resulting foreign currency transactions translated using average spot exchange rate balance sheet date realisation principle section conjunction section halfsentence hgb historical cost convention section conjunction section sentence hgb applied items remaining term one year consolidated financial statements financial statements foreign subsidiaries domiciled state outside eurozone denominated foreign currency converted euros accordance section hgb using modified closing date rate method using modified closing date rate method asset liability items annual financial statements prepared foreign currency translated euros using average spot exchange rate balance sheet date exception equity translated using historical rate items included profit loss statement translated euros using average rate resulting translation difference reported within consolidated equity reserves balance sheet currency conversion difference annual financial statements countries hyperinflation significant foreign currency items translated prior year exchange rates temporal method improve true fair view groups net assets financial earnings position product portfolio exchange rates groups important currencies changed follows reporting year basis eur closing rate average annual rate us dollar japanese yen pound sterling chinese renminbi accounting policies fixed assets acquired intangible assets tangible fixed assets carried cost less scheduled straightline amortisation depreciation determined consideration technical economic circumstances based following useful lives intangible assets years buildings years technical equipment machinery years equipment operating office equipment years straightline depreciation amortisation used consolidated financial statements additional writedowns recorded reflect impairments value assets considered permanently impaired production costs include materials labour manufacturing costs appropriate portion materials labour overheads depreciation fixed assets extent caused production capitalised intangible assets finite useful lives financial assets primarily include shareholder rights securities loans carried lower cost fair market value impaired consolidated financial statements notes boehringer ingelheim c urrent assets prepaid expenses deferred charges exceeding amount plan assets inventories carried lower cost fair market value raw materials consumables supplies capitalised lower average acquisition prices fair market value balance sheet date finished goods work progress measured production cost basis individual calculations taking account directly attributable costs materials direct labour costs special direct costs appropriate share production material overhead costs depreciation goods resale valued lower either purchase cost fair market value identifiable risks inventory assets arising aboveaverage storage periods diminished marketability lower replacement costs taken account recording appropriate valuation adjustments inventories valued lossfree e deductions made expected sales prices reflect costs yet incurred receivables assets recognised cost less allowances specific risks general credit risk lowinterest noninterestbearing receivables term one year discounted securities classified current assets include securities recognised lower cost quotedmarket prices reporting date cash cash equivalents consisting cash balances banks cheques recognised lower cost fair market value prepaid expenses recorded accordance section hgb include expenses paid advance respect defined period time balance sheet date deferred charges recorded accordance section hgb include proceeds represent income respect defined period time balance sheet date fair market value plan assets corresponding present value pension obligation offset according german gaap exceeding amount plan assets capitalised separately product portfolio difference capital consolidation difference capital consolidation reported december previous year resulted almost exclusively acquisition us company original difference amounted eur mil lion difference amortised estimated period ten years remaining balance difference amounted eur million december reduction due release eur million current period due effect changes exchange rate addition increase difference capital consolidation reported december result exchange business areas boehringer ingelheims consumer health care business chc sanofis animal health business merial completed january accordance accounting policy selected boehringer ingelheim application exchange principles book value method acquisition cost shareholdings merial companies acquired sanofi equal cash compensation including assumed obligations eur million plus carrying amount chc business transferred exchange eur million proportional equity share merial companies january eur million corresponded fair value acquired assets liabilities taking noncontrolling interests account resulted difference capital consolidation eur million amortisation period difference transaction estimated years remaining carrying amount difference december release eur million current financial year amounted eur million release financial year influenced oneoff effects primarily consequence tax reform usa income release difference arising capital consolidation included operating income release made corresponding amortisation assets acquired company identified purchase price allocation previously recognised companys balance sheet hid den assets group reserves group reserves include retained earnings consolidated subsidiaries prior current years consolidation entries affect earnings provisions tax provisions provisions include uncertain liabilities expected losses executory contracts carried amount required settle obligation based reasonable prudent commercial judgement e including future cost price increases provisions remaining maturity one year discounted using matchedterm average market interest rate case pension provisions interest rate results last ten years case provisions last seven years accordance rckstellungsabzinsungsverordnung german regulation discounting provisions accounts payable loans accounts payable loans recognised settlement amount consolidated financial statements notes boehringer ingelheim deferred taxes calculate deferred taxes arising tax loss carry forwards temporary quasipermanent differences carrying amounts assets liabilities prepaid expenses deferred charges commercial balance sheet carrying amounts tax purposes amounts resulting tax benefits expenses time differences reverse measured using tax rates specific respective consolidated company deferred tax balances discounted differences due consolidation measures accordance sections hgb also measured using company specific tax rates applicable time expected reversal difference deferred tax assets loss carryforwards taken account likely used within next five years deferred tax assets liabilities reported without offsetting explanation comparability previous years figures result exchange consumer health care business chc sanofis animal health business merial significant change composition consolidated companies financial year order provide better comparability consecutive consolidated financial statements significant balance sheet profit loss statement items adjusted consumer health care business discontinued newly acquired animal health business balance sheet millions eur incl merial thereof merial excl merial incl chc thereof chc excl chc fixed assets current assets liabilities explanation decrease adjusted current assets reported december please refer chapter notes profit loss statement thereof millions eur incl merial merial tdsa chc excl merial incl chc thereof chc excl chc net sales numbers earnings chc business unit based management reporting c h boehringer sohn ag co kg diverge actual transaction amounts difference significant product portfolio order derive comparable figures net sales must adjusted newly acquired animal health business also sales governed transitional services production agreements part transaction sanofi tdsatsa information performance adjusted net sales please refer statements report eco nomic position management report operating expenses income previous year subject significant positive negative extraordinary onetime effects means comparative presentation similar manner net sales result better comparability regard extraordinary onetime effects please refer chapter notes change personnel expenses corresponded change number employees overall employees transferred sanofi transferred group disposal consumer health care business cost materials besides increase newly aquired animal health business subject exceptional effects means comparative presentation similar manner net sales result better comparability regard exceptional effects please refer chapter notes besides addition animal health business capital intensive chc business increase depreciation amortisation tangible intangible fixed assets primarily due amortisation intangible assets aquired within transaction consolidated financial statements notes boehringer ingelheim notes consolidated balance sheet intangible assets acquired concessions advance millions eur similar rights goodwill payments total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value product portfolio tangible assets advance technical facilities payments land facilities operating construction millions eur buildings machines equipment progress total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value consolidated financial statements notes boehringer ingelheim financial assets investments loans investments affiliated affiliated related advance investment millions eur companies companies companies payments securities loans total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated amortisation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value previous year loans item include loans shareholders product portfolio inventories millions eur raw materials supplies unfinished goods finished goods goods resale advance payments suppliers accounts receivable assets residual residual term term millions eur year year trade accounts receivable receivables affiliated companies receivables related companies assets assets item includes receivables shareholders eur million previous year eur million receivables affiliated companies almost exclusively consist receivables loans receivables related companies primarily consist trade accounts receivable provisions millions eur provisions pensions similar obligations tax provisions provisions consolidated financial statements notes boehringer ingelheim provisions pensions similar obligations provisions pensions similar obligations determined basis actuarial calculations using projected unit credit method taking account future adjustments salaries pensions addition local biometric data eg germany mortality tables g published prof dr klaus heubeck pension obligations significant countries calculated basis following actuarial parameters december germany usa japan discount rate salary increase pension increase discounting rates determined reference average market rates year maturities accordance german regulation discounting provisions march interest rates used discount significant foreign pension obligations usa japan determined comparable parameters line german regulation discounting provisions march difference calculated accordance section hgb amounts eur million plan assets intended solely cover pension similar obligations unavailable creditors plan assets defined section sentence hgb measured fair market value essentially derived stock market prices offset underlying pension similar obligations fair market value plan assets balance sheet date eur million related amount pension obligations similar obligations eur million gains losses plan assets interest expense relating pension similar obligations offset accordance section sentence hgb total eur million earnings plan assets eur million interest expense relating pension similar obligations included financial result tax provisions tax provisions also include provisions double taxation risks resulted following imple mentation action plans organisation economic cooperation development oecd part international initiative known action plan base erosion profit shifting beps provisions provisions mainly include provisions discounts guarantees provisions litigation legal claims compensation damages provisions outstanding invoices provisions assumed risks course business exchange sanofi well personnelrelated provisions product portfolio accounts payable loans residual term residual term less greater greater less millions eur year year years year bank loans accounts payable trade accounts payable advance payments received accounts payable affiliated companies accounts payable related companies liabilities taxes eur million social security liabilities eur million previous year liabilities secured mortgages similar collateral rights balance sheet date end year liabilities shareholders eur million previous year eur million presented within liabilities item accounts payable affiliated companies include loans amounting eur million previous year eur million trade accounts payable amounting eur million previous year eur million consolidated financial statements notes boehringer ingelheim notes consolidated profit loss statement structure consolidated profit loss statement based total cost format taxes included operating expenses net sales business business segment millions eur human pharmaceuticals animal health biopharmaceuticals industrial customers sales dicontinued operations geographic region millions eur europe germany americas usa asiaaustraliaafrica japan operating income operating income financial year includes exceptional onetime income amounting eur million particular result sale business usa order adjust animal health product portfolio antitrust reasons well due release provisions operating income includes income currency translation eur million previous year eur million cost materials millions eur costs raw material supplies goods resale expenditure services product portfolio cost materials affected impact sales inventory newly acquired merial companies inventories valued market value january eur million personnel expenses millions eur wages salaries social benefits retirement benefits retirement benefits interest effects measurement provisions pensions similar obligations shown separate item financial income average headcount production administration marketing sales research development apprentices amortisation intangible assets depreciation tangible assets amortisation intangible assets depreciation tangible fixed assets include extraordinary writedowns eur million previous year eur million operating expenses operating expenses include expenses currency translation eur million previous year eur million total operating expenses affected impact exceptional onetime expenses amounting eur million connection exchange business areas sanofi addition items included operating expenses mainly charges made record provisions legal risks restructuring well thirdparty services research development medicine marketing purposes administrative expenses fees contributions commissions rent freight expenses repairs carried third parties consolidated financial statements notes boehringer ingelheim financial income millions eur interest expense relating pensions similar obligations provisions interest expense similar expenditure interest expense similar expenditure amortisation loss disposal financial assets shortterm investments income investment securities longterm loans interest income similar proceeds holding income millions eur writeoffs financial assets income related companies disposal related companies income taxes millions eur current income taxes deferred taxes income tax expense also affected significant extraordinary effects tax expense current period includes tax expenses arising disposal chc business approximately eur billion moreover usa tax reform approved december tax cuts jobs act required reassessment deferred tax assets liabilities corporate income tax rate enacted law balance sheet date future financial years also resulted significant increase tax expense eur million current income taxes primarily include corporation trade tax expenses companies included consolidation total balance deferred tax assets balance sheet amounted eur million previous year eur million deferred tax assets primarily arise difference carrying amounts provisions pension obligations discounts tax goodwill fixed assets inventories deferred tax liabilities eur million previous year eur million recorded primarily relate differences carrying amounts intangible assets tangible assets inventories provisions product portfolio group loss group loss positively influenced priorperiod operating income primarily reversal provisions eur million previous year eur million negatively influenced priorperiod operating expenses eur million previous year eur million notes cash flow statement cash flow statement shows changes cash cash equivalents cash longterm securities investments classified current assets sold time boehringer ingelheim group resulting cash outflows reporting year accordance german accounting standard cash flow statement drs cash flow statement broken according cash flows operating activities cash flows investing financing activities changes balance sheet items affiliated companies included translated using average rates year balance sheet cash cash equivalents carried closing rate effect exchange rate changes cash cash equivalents shown separately financial funds also include financial assets remaining maturity excess three months date acquisition financial assets converted cash shortterm financial funds december comprised following items millions eur cash cash equivalents securities financial assets financial funds included eur million restricted funds balance sheet date financial year interest eur million previous year eur million received interest eur million previous year eur million taxes eur million previous year eur million paid consolidated financial statements notes boehringer ingelheim disclosures contingent liabilities millions eur liabilities guarantees warranties granting securities thirdparty liabilities risk utilisation contingent liabilities assessed low account good net assets financial position earnings financial commitments offbalance sheet transactions millions eur rental leasing obligations purchase commitment obligations rental lease agreements eur million previous year eur million eur million previous year eur million relate longterm rental agreements sub sidiaries included consolidation purpose lease agreements lower capital commitment compared buying property absence resale risk risks could arise term lease possible continue utilise properties fully indications time financial commitments include future expenses followup investments investments already initiated future major repairs balance sheet date purchase commitments include future cash flow effects investments totalling eur million previous year eur million derivative financial instruments valuation units due extensive international structure boehringer ingelheim group highly dependent devel opments worlds currencies interest rates hedge risks particularly emerging goods services financing currency forwards options generally used currency risks interest rate swaps options used interest rate risks use derivative financial instruments organisational processes set internal guidelines strict separation trading processing documentation control product portfolio risk positions regularly tracked analysed measured special groupwide financial report positions entered periodically reevaluated monitored fair value derivative financial instruments calculated using generally accepted market valuation methods currency forwards based present value method taking account market data balance sheet date provisions eur million recognised currency forwards included hedge accounting negative fair value within one currency balance sheet date line imparity principle positive fair values within one currency recognised balance sheet date derivative financial instruments included hedge accounting valuation groups follows nominal value fair value millions eur foreign exchange forward contracts extent requirements hedge accounting foreign currency forward exchange contracts highly probable forecasted transactions accordance section hgb met foreign currency forward exchange contracts recognised balance sheet line net hedge presenta tion method following accounting policies apply recognition valuation groups accordance ection hgb economic hedges accounted financial statements use valuation groups valuation groups recognised foreign currency based net amount highly probable forecasted transactions currency forwards match forecasted net cash flow terms maturity nominal amount foreign currency macro hedge highly probable forecasted transactions incoming outgoing payments planned sales purchases derived company planning expost analysis planning shown planned transactions highly probable opposing changes value hedged item hedging instrument fully offset critical terms maturity nominal amount foreign currency match effective hedge therefore assumed prospectively retrospectively critical term match method exclusively used measure prospective retrospective effectiveness hedges excess amounts hedging transactions included valuation groups consolidated financial statements notes boehringer ingelheim december hedges highly probable forecast net cash flows recognised follows january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value fair value usd usd usd jpy jpy jpy january february net cash flow millions eur fx forward contracts millions eur nominal value nominal value fair value usd usd usd jpy jpy jpy years also hedge accounting valuation groups long short posi tions derivatives offsetting nominal values amount eur million japanese yen eur million us dollar product portfolio furthermore december valuation groups foreign currency receivables recognised follows receivables millions eur forward exchange contracts millions eur nominal value nominal value fair value rub rub rub pln pln pln amount hedged foreign currency risk correlates relative change exchange rate planning date realisation date forecast transactions currencies appreciate depreciate euro would foreign currency risk plus minus eur million without hedging research development expenses millions eur research development expenses noncapitalised research development expenses include amongst items costs associated clinical studies report postbalance sheet date events since end financial year become aware events material significance group could lead reappraisal net assets financial position earnings total auditor fees total fees charged group auditor financial year amounted eur million eur million relates audits financial statements eur million assurance services eur million tax advisory services eur million services independent auditors report boehringer ingelheim independent auditors report c h boehringer sohn ag co kg ingelheim qualified audit opinion consolidated financial statements audit opinion group management report audited consolidated financial statements c h boehringer ingelheim sohn ag co kg ingelheim subsidiaries group comprise consolidated balance sheet december consolidated income statement consolidated statement changes equity consolidated cash flow statement financial year january december notes consolidated financial statements including recognition measurement policies presented therein addition audited group management report ch boehringer ingel heim sohn ag co kg financial year january december opinion basis knowledge obtained audit except effects matter described section basis qualified audit opinion consolidated financial statements audit opinion group management report accompanying consolidated financial statements comply material respects requirements german commercial law consolidated financial statements give true fair view assets liabilities financial position group december financial performance financial year january december compliance german legally required accounting principles accompanying group management report whole provides appropriate view groups position material respects group management report consistent consolidated financial statements complies german legal requirements appropriately presents oppor tunities risks future development pursuant article abs paragraph satz sentence hgb handelsgesetzbuch german commercial code declare except qualification audit opinion consolidated financial statements mentioned audit led reservations relating legal compliance consolidated financial statements group management report basis qualified audit opinion consolidated financial statements audit opinion group management report contrary abs nr number buchstaben letters b hgb total remuneration granted members former members board managing directors well pension provisions recognized recognized former members board managing directors disclosed notes consolidated financial statements product portfolio conducted audit consolidated financial statements group management report accordance hgb compliance german generally accepted standards financial statement audits promulgated institut der wirtschaftsprfer institute public auditors germany idw responsibilities requirements principles described auditors responsibilities audit consolidated financial statements group management report section auditors report independent group entities accordance requirements german commercial professional law fulfilled german pro fessional responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis qualified audit opinion consolidated financial statements audit opinion group management report information executive directors responsible information information comprises annual report excluding crossreferences external information exception audited consolidated financial statements audited group management report auditors report audit opinions consolidated financial statements group management report cover information consequently express audit opinion form assurance conclusion thereon connection audit responsibility read information consider whether information materially inconsistent consolidated financial statements group management report knowledge obtained audit otherwise appears materially misstated responsibilities executive directors consolidated financial statements group management report executive directors responsible preparation consolidated financial statements comply material respects requirements german commercial law consoli dated financial statements give true fair view assets liabilities financial position financial performance group compliance german legally required accounting principles addi tion executive directors responsible internal control accordance german legally required accounting principles determined necessary enable preparation consolidated financial statements free material misstatement whether due fraud error independent auditors report boehringer ingelheim preparing consolidated financial statements executive directors responsible assessing groups ability continue going concern also responsibility disclosing applicable matters related going concern addition responsible financial reporting based going concern basis accounting provided actual legal circumstances conflict therewith furthermore executive directors responsible preparation group management report whole provides appropriate view groups position material respects consistent consolidated financial statements complies german legal requirements appropriately presents opportunities risks future development addition executive directors responsible arrangements measures systems considered necessary enable preparation group management report accordance applicable german legal requirements able provide sufficient appropriate evidence assertions group management report auditors responsibilities audit consolidated financial statements group management report objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error whether group management report whole provides appropriate view groups position material respects consistent consolidated financial statements knowledge obtained audit complies german legal requirements appropriately presents opportunities risks future development well issue auditors report includes audit opinions consolidated financial statements group management report reasonable assurance high level assurance guarantee audit conducted accordance hgb compliance german generally accepted standards financial statement audits promulgated institut der wirtschaftsprfer idw always detect material misstatement misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consolidated financial statements group management report product portfolio exercise professional judgment maintain professional skepticism throughout audit also identify assess risks material misstatement consolidated financial statements group management report whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis audit opinions risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit consolidated financial statements arrangements measures systems relevant audit group management report order design audit procedures appropriate circumstances purpose expressing audit opinion effectiveness systems evaluate appropriateness accounting policies used executive directors reasona bleness estimates made executive directors related disclosures conclude appropriateness executive directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated financial statements group management report disclosures inadequate modify respective audit opinions conclusions based audit evidence obtained date auditors report however future events condi tions may cause group cease able continue going concern evaluate overall presentation structure content consolidated financial statements including disclosures whether consolidated financial statements present underlying transactions events manner consolidated financial statements give true fair view assets liabilities financial position financial performance group compliance german legally required accounting principles obtain sufficient appropriate audit evidence regarding financial information entities business activities within group express audit opinions consolidated financial statements group management report responsible direction supervision performance group audit remain solely responsible audit opinions evaluate consistency group management report consolidated financial statements conformity german law view groups position provides independent auditors report boehringer ingelheim perform audit procedures prospective information presented executive directors group management report basis sufficient appropriate audit evidence evaluate particular significant assumptions used executive directors basis prospective information evaluate proper derivation prospective information assumptions express separate audit opinion prospective information assumptions used basis substantial unavoidable risk future events differ materially prospective information communicate charged governance regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit frankfurt main march pricewaterhousecoopers gmbh wirtschaftsprfungsgesellschaft dr ulrich strk michael conrad wirtschaftsprfer wirtschaftsprfer german public auditor german public auditor product portfolio p r u c p r f l e l e c n human pharmaceuticals animal health product portfolio human pharmaceuticals boehringer ingelheim respiratory diseases respiratory diseases common chronic obstructive bronchial asthma pulmonary disease copd bronchial asthma bronchial asthma chronic inflammatory disorder among prevalent chronic diseases frequent airways inflammation accompanied airway cause morbidity premature deaths worldwide hyperresponsiveness leads narrowing airways recurrent episodes wheezing breathless idiopathic pulmonary fibrosis ipf rare disease ness coughing symptoms occur particularly severely debilitating ultimately lethal night early hours morning known asthma triggered genetic envi copd ronmental factors eg allergens viral infections copd chronic disease lungs causes cough unlike copd asthma occur early childhood ing excessive mucus production dyspnea ulti also present adolescents adults asthma mately destroys lung tissue alveoli thus gas often underestimated easytomanage condition exchange affected leads limitation however almost one two patients asthma still airflow causing shortness breath respira experience symptoms receiving maintenance ther tory symptoms airflow limitation partially apy putting increased risk potentially reversible usually worsens time leading disa lifethreatening asthma exacerbations addition bility ultimately death symptoms excess patients often adjust daily lives accommodate cough breathlessness main reasons copd conditions avoid physical exertion daytoday stressful patients lung emphysema chronic activities negative impact quality life bronchitis main manifestations copd copd caused continuous damage lungs result ing inhaling pollutants primarily cigarette smoke however factors also need considered includ ing indoor outdoor air pollution course copd disease occurs second half humans life characterised accelerated loss lung function compared normal ageing occasional sudden worsening symptoms function referred acute exacerbations lead downward spiral worsening symptoms thus fur ther inactivity indications brand names active ingredients chronic obstructive spiriva tiotropium bromide maintenance treatment patients pulmonary disease copd spiriva handihaler copd including chronic bronchitis spiriva respimat emphysema maintenance treatment associated dyspnoea prevention exacerbations bronchial asthma spiriva respimat tiotropium bromide addon maintenance treatment adult patients asthma currently treated maintenance combination inhaled corticosteroids spiriva respimat approved use asthma eu japan usa many countries label varies country please refer local product information chronic obstructive spiolto respimat tiotropium bromide maintenance treatment airflow pulmonary disease copd stiolto respimat olodaterol obstruction patients chronic inspiolto respimat hydrochloride obstructive pulmonary disease copd chronic obstructive striverdi respimat olodaterol maintenance treatment patients pulmonary disease copd hydrochloride chronic obstructive pulmonary disease copd reversible bronchospasms combivent respimat ipratropium bromide combination shortacting associated obstructive salbutamol sulphate anticholinergic betaadrenergic airway diseases management reversible broncho spasms associated obstructive airway diseases patients requiring one bronchodilator chronic obstructive atrovent ipratropium bromide prevention treatment shortness pulmonary disease copd breath patients chronic chronic bronchitis obstructive pulmonary disease copd bronchial asthma mild moderate bronchial asthma adulthood childhood supple ment betaagonists cases acute asthma chronic obstructive airway berodual ipratropium bromide fenoterol prevention treatment symptoms disorders bronchodual hydrobromide chronic obstructive airway disorders duovent reversible airflow limitation bronchial asthma especially chronic bronchitis without emphysema product portfolio human pharmaceuticals boehringer ingelheim respiratory diseases continued idiopathic pulmonary fibrosis ipf acute ipf exacerbations defined rapid deteriorations ipf chronic progressive lung disease associated symptoms lung function within days weeks markedly reduced life span affecting many events occur point course disease people per worldwide ipf characterised even first presentation associated high mor progressive scarring lung tissue loss lung tality patients ipf risk acute ipf exacer function time development scarred tissue called bations fibrosis time tissue thickens stiffens scarring lungs lose ability take transfer oxygen blood stream vital organs get enough oxygen result individuals ipf experience shortness breath even resting often difficulty coping demands everyday life due limited physical capacity indications brand names active ingredients bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attacks prophylaxis exerciseinduced asthma bronchiale symptomatic treatment allergic nonallergic asthma bronchiale conditions reversible airway narrowing eg chronic obstructive b ronchitis bronchial asthma alesion epinastine hydrochloride prophylactic treatment patients allergic rhinitis flurinol bronchial asthma prophylaxis symp tomatic treatment allergic rhinitis idiopathic pulmonary fibrosis ofev nintedanib treatment patients idiopathic ipf pulmonary fibrosis ipf product portfolio human pharmaceuticals boehringer ingelheim cardiovascular metabolic diseases cardiovascular cv disease leading cause death prevention treatment venous many countries still increasing prevalence thromboembolism currently responsible nearly one three deaths venous thromboembolism vte umbrella term worldwide one key risk factor developing cardio encompasses deep vein thrombosis dvt pulmonary vascular disease presence diabetes people embolism pe dvt process occurs diabetes two four times likely develop thrombus blood clot forms deep vein commonly cardiovascular disease people without diabetes calf leg partially completely blocks result life expectancy years shorter flow blood thrombus grows portion may proper control diabetes treatable risk factors break away main clot travel circulatory therefore vital prevention cardiovascular events system lungs lodging blood clot arteries lung called pe vte serious disor stroke der potentially fatal consequences stroke rapidly developing loss brain functions caused reduced blood flow affected brain tis patients undergoing orthopaedic surgery considerable sue due ischaemia lack blood supply risk developing dvt chronic venous insufficiency caused thrombosis embolism due bleeding andor pulmonary hypertension may develop longer result affected area brain unable term prevent vte events consequences function damage quickly becomes permanent orthopaedic surgery patients receive kind untreated stroke acute event requiring emergency thromboprophylaxis patients already suffered diagnosis intervention worldwide stroke one vte require anticoagulant treatment secondary leading causes death longterm disability prevention recurrent thromboembolic event symptoms transient ischaemic attack tia similar stroke last minutes hours reversing anticoagulation usually result permanent neurological damage anticoagulants offer important benefits patients risk tia may precede stroke emergency medical care thromboembolic events however even though rare subsequent preventive treatment may necessary situations rapid reversal anticoagu lation could medically necessary eg patient taking atrial fibrillation anticoagulant involved severe car accident atrial fibrillation af common sustained needs emergency surgery heart rhythm condition affecting approximately total population one four adults develops arrhythmia lifetime patients af higher risk developing blood clots upper left heart chamber cause disabling stroke clot breaks loose travels brain af leads fivefold increase risk stroke result ing three million patients worldwide suffering afrelated strokes year risk stroke reduced effective chronic anticoagulation indications brand names active ingredients stroke prevention atrial pradaxa dabigatran etexilate prevention strokes blood clots fibrillation pradaxar patients abnormal heart rhythm primary prevention venous prazaxa atrial fibrillation thromboembolic events primary prevention venous thrombo orthopaedic surgery embolic events vte adults treatment secondary elective total hip knee replacement prevention venous throm surgery boembolic events treatment deep vein thrombosis dvt pulmonary embolism pe secondary prevention recurrent dvt pe adults specific reversal pradaxa praxbind idarucizumab praxbind specific reversal agent dabigatran etexilate dabigatran indicated dult patients treated pradaxa dabigatran etexilate rapid reversal anticoaculant effects required emergency surgeryurgent procedures lifethreatening uncontrolled bleeding hypertension micardis telmisartan treatment hypertension cardiovascular morbidity micardisplus telmisartan hydrochlorothiazide reduction risk myocardial mortality prevention micardis plus infarction heart attack stroke death cardiovascular cv causes micardis hct patients years age older high comicardis risk developing major cv events unable take ace inhibitors usa reduction cardiovascular mor bidity patients manifest athero thrombotic cardiovascular disease history coronary heart disease stroke peripheral arterial disease patients type diabetes mellitus docu mented target organ damage eu h ypertension twynsta telmisartan amlodipine treatment hypertension alone micamlo antihypertensive agents initial micardis amlo therapy patients likely need multi ple antihypertensive agents achieve micardis duo blood pressure goals usa addon therapy adult patients adequately controlled blood pres sure amlodipine replacement therapy adult patients receiving tel misartan amlodipine separate tablets eu product portfolio human pharmaceuticals boehringer ingelheim cardiovascular metabolic diseases continued hypertension cardiovascular diseases hypertension also referred high blood pressure chronic disease blood pressure chronically elevated hypertension also one major risk factors stroke heart attacks heart failure chronic renal failure primary goal antihypertensive treatment prevent cardiovascular events reduce cardiovascular mortality acute myocardial infarction acute myocardial infarction heart attack event occurs thrombus clot suddenly pre vents blood flow area heart muscle unless blood flow restored quickly affected section heart muscle becomes permanently damaged heart attack leading cause death developed countries indications brand names active ingredients acute ischaemic stroke actilyse alteplase fibrinolytic treatment acute ischae acute myocardial infarction actilyse cathflo mic stroke acute myocardial infarction acute massive pulmonary acute massive pulmonary embolism embolism fibrinolytic treatment occluded catheter clearance due catheters thrombotic occlusion secondary prevention aggrenox dipyridamole prevention stroke following initial stroke transient ischaemic asasantin acetylsalicylic acid first stroke transient ischaemic attacks tia asasantin retard attacks tia acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocar dial infarction hypertension catapresan clonidine treatment hypertension catapres clonidine hydrochloride catapressan cataprestts hypertension motens lacidipine treatment hypertension product portfolio human pharmaceuticals boehringer ingelheim cardiovascular metabolic diseases continued diabetes overall around half deaths people type dia type diabetes chronic progressive condition associated betes caused concomitant cardiovascular disease elevated blood sugar levels cause longterm indicating high unmet medical need complications treated addition cardiovascular disease serious complications approximately million deaths worldwide every year diabetes include linked directly longterm effects diabetes type diabetes common form disease nephropathy culminating renal failure requiring accounts cases developed world dialysis currently million people world live retinopathy potential loss vision diabetes represents enormous burden peripheral neuropathy risk developing foot health care systems globally without effective pre vention ulcers potentially requiring foot leg amputations management strategies estimated num autonomic neuropathy cause gastrointestinal ber cases reach million genitourinary cardiovascular symptoms sexual dysfunction addition type diabetes one major risk factors cardio vascular disease life expectancy people type dia betes high cardiovascular risk decreases average years indications brand names active ingredients type diabetes mellitus trajenta linagliptin treatment type diabetes mellitus tradjenta adjunct diet exercise trazenta improve glycaemic control adults used monotherapy metformin trayenta tolerated contraindicated combination therapy type diabetes mellitus jentadueto linagliptin metformin hydrochloride treatment type diabetes mellitus trayenta duo adjunct diet exercise trajenta duo improve glycaemic control adults treatment metformin trajentamet lead sufficient control patients treated trajenta linagliptin metformin type diabetes mellitus jardiance empagliflozin treatment adults type diabetes jardianz mellitus adjunct diet exer cise improve glycaemic control reduce risk cardiovascular death adults type diabetes mellitus established cardiovascular disease usa indication december label varies country please refer local product information type diabetes mellitus synjardy empagliflozin treatment type diabetes mellitus jardiance duo metformin adjunct diet exercise improve hydrochloride glycaemic control adults treat ment empagliflozin met formin hydrochloride appropriate usa indication december label varies country please refer local product information type diabetes mellitus glyxambi empagliflozin linagliptin treatment type diabetes mellitus adjunct diet exercise improve glycaemic control adults type diabetes mellitus empagli flozin linagliptin appropriate treatments usa indication march label varies country please refer local product information iabetes portfolio collaboration eli lilly company product portfolio human pharmaceuticals boehringer ingelheim oncology cancer threat global health estimated unspecific disease may take many years million new cases cancer diagnosed world appear late diagnosis advanced stage disease wide million people died cancer nearly one results often dismal prognosis six global deaths world cancer factsheet lung cancer patients surviving five years follow common diagnosed cancer types lung ing diagnosis cer nearly liver cancer colorectal cancer stomach cancer breast cancer lung cancer one disease dif ferent subtypes small cell lung cancer sclc lung cancer nonsmall cell lung cancer nsclc differ lung cancer refers malignant abnormal cell growth ent molecular genetic aberrations mutations present inside lung tissue forming cluster tumour tumour identified focusing molecular common cancer estimated million new changes specific respective subtype lung cases per year worldwide smoking primary cancer targeted therapies become effective cause disease contributing nearly cases treatments show survival benefit recently however incidence lung cancer among time less harmful normal cells thereby nonsmokers increased lung cancer poor prog reducing side effects nosis million deaths per year representing nearly cancer deaths lung cancer symptoms indications brand names active ingredients nonsmall cell lung cancer giotrif afatinib firstline treatment patients nsclc gilotrif metastatic nonsmall cell lung cancer nsclc whose tumours activating epidermal growth factor receptor egfr mutations treatment patients locally advanced metastatic nsclc squamous histology progress ing platinumbased chemo therapy nonsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patients locally advanced metastatic locally nonsmall cell lung cancer nsclc adenocarcinoma tumour histology firstline chemotherapy product portfolio human pharmaceuticals boehringer ingelheim diseases central nervous system mental neurological diseases depression depression sleep disorders primary symptoms parkinsons disease significantly impact patients result lack neurotransmitter dopamine families also substantial burden society distinct areas human brain parkinsons disease restless legs syndrome rls parkinsons disease pd degenerative disorder restless legs syndrome rls common neurological central nervous system patients usually notice motor disorder characterised uncontrollable urge move symptoms like hand tremor shaking first sign legs primarily occurring evening night disease may progress include shaking hours usually accompanied unpleasant arms legs head motor symptoms may times painful sensations legs well disturbed develop time include stiffness often results sleep resulting daytime tiredness sleepiness loss facial expression gradual slowing loss sensations felt deep within legs described motion freezing patients also creeping crawling aching suffer nonmotor symptoms associated pd infectious diseases hiv infectionaids acquired immune deficiency syndrome aids set symptoms infections resulting damage human immune system caused human immu nodeficiency virus hiv untreated infection hiv progressively reduces effectiveness immune system leaves individuals susceptible opportunistic infections tumours babies infected mothers risk getting virus pregnancy childbirth breastfeeding indications brand names active ingredients parkinsons disease pd sifrol pramipexole symptomatic treatment idiopathic restless legs syndrome rls mirapex parkinsons disease may used mirapexin monotherapy combination levodopa symptomatic treatment pexola idiopathic moderate severe restless legs syndrome sleep disorders lendormin brotizolam shortterm treatment disorders initiating maintaining sleep insomnia requiring pharmacological intervention indications brand names active ingredients hivaids viramune nevirapine combination therapy hiv viramune xr infection several countries prevention mothertochild transmission hiv pregnant women taking antiretroviral therapy time labour prolonged release tablets oncedaily dosing within combination therapy hivaids aptivus tipranavir indicated combination antiretroviral treatment hivinfected patients coadministered mg ritona vir treatmentexperienced infected hiv strains resistant one protease inhibitor product portfolio animal health boehringer ingelheim livestock swine infectious respiratory diseases infectious enteric diseases ingelvac circoflex first singledose piglet vaccine enterisol ileitis first oral live vaccine control porcine circovirus disease pcvd ileitis globally prevalent enteric disease vaccine provides significant reduction mortality caused lawsonia intracellularis licensed acute phase pcvd well improved growth rates improve weight gain reduce growth variability chronic phase disease ingelvac circoflex associated disease enterisol ileitis helps protects minimal systemic adverse reactions reduce total antimicrobial use pork production injection site swellings used gestation lactation ingelvac prrs products licensed active immunisation respiratory repro ductive form porcine reproductive respiratory syndrome prrs ingelvac mycoflex provides proven safety efficacy rapid onset longlasting immunity myco plasma hyopneumoniae hyo single dose ingelvac mycoflex contains impranflex adju vant allows fresh mixing ingelvac c ircoflex form flexcombo indications brand names active ingredients infectious respiratory ingelvac circoflex recombinant vaccine active immunisation pigs diseases porcine circovirus age two weeks porcine type pcv circovirus type reduce mortality clinical signs including weight loss lesions lymphoid tissues asso ciated porcine circovirus diseases pcvd addition vaccination shown reduce pcv nasal shed ding viral load blood lymphoid tissues duration viraemia infectious respiratory ingelvac prrs mlv attenuated live vaccine prrs virus depending product diseases ingelvac prrsflex eu type active immunisation pigs various reprocyc prrs eu type ages porcine reproductive respiratory syndrome virus prrsv infectious respiratory ingelvac mycoflex inactivated vaccine active immunisation pigs diseases mycoplasma age three weeks reduce lung hyopneumoniae lesions following infections myco plasma hyopneumoniae infectious enteric diseases enterisol ileitis attenuated live vaccine active immunisation pigs lawsonia age three weeks intestinal intracellularis lesions caused lawsonia intracellularis infection reduce growth variability loss weight gain associated disease product portfolio animal health boehringer ingelheim livestock cattle cattle business global leader antiparasitic brands ivomec longrange eprinex world renowned parasiticides treat protect grazing animals harmful effects internal external parasites zactran treats cattle bacterial pneumonia sheep digital dermatitis infections vaccine pyramidpresponse part ex pand ing portfolio respiratory reproductive vaccines prevent diseases affect livestock indications brand names active ingredients internal external ivomec ivermectin depending formulation product parasites cattle treatment nematodes lice mites ticks flies lungworms liver flukes internal external longrange eprinomectin longacting theraphase technology used parasites cattle develop formulation eprinomectin allows single treatment last days long enough break parasite life cycle effectively reduce parasite burdens pasture longrange effective control internal external parasites cattle gastrointestinal roundworms lungworms grubs mites internal external eprinex eprinomectin depending formulation product parasites ruminants treatment nematodes lice mites ticks flies lungworms cattle sheep bacterial causes respiratory zactran gamithromycin depending species indication disease interdigital country registration product dermatitis footrot treatment metaphylaxis control key bacteria causing respira tory disease cattle mannheimia pasteurella histophilus mycoplasma key bacteria causing footrot disease sheep fusobacterium dichelobacter respiratory reproductive pyramid family multivalent vaccine combi pyramidpresponse family infectious diseases cattle presponse nations including different modified vaccines provides broad coverage live viruses bvd types ibr brsv pi bovine viral diarrhoea bvd types mannheimia haemolytica infectious bovine rhinotrache single dose contain metastim itis ibr parainfluenza pi adjuvant system enhance animals bovine respiratory syncytial virus response greater protection us brsv bacteria pasteurella canada multocida mannheimia haemolyt ica l canicola l grippotyphosa l hardjo l icterohaemmorrhagiae l pomona product portfolio animal health boehringer ingelheim livestock poultry volvac umbrella brand poultry vaccine range consists wide range live inactivated vaccines broilers layers vaccines provide protection birds various viral bacterial diseases like avian influenza infectious bronchitis newcastle disease infectious bursal disease egg drop syndrome avian coryza acquisition merial enlarged portfolio additional vaccines include several leaders respective segments indications brand names active ingredients various viral bacterial volvac polyvalent attenuated live vaccination healthy chickens diseases poultry inactivated vaccine diseases caused included containing antigens antigens prevention vaccination avian common diseases broiler chickens influenza newcastle diseases responsible losses disease avian coryza egg egg production layers drop syndrome infectious bronchitis infectious bursal disease gallibacterium anatis vaccine infectious vaxxitekhvt ibd serotype live mareks disease prevent mortality reduce bursal disease mareks vector clinical signs lesions infectious disease bursal disease onset protection live vhvt recombinant two weeks protection virus diluent extends nine weeks reduce mortality clinical signs lesions mareks disease onset protection four days single vaccination sufficient provide protection risk period vaccine salmonella gallimune bivalent vaccine active immunisation layer pullets enteritidis se oily adjuvant reduce salmonella enteritidis salmonella typhimurium st dissemination ovary reduce inactivated salmonella salmonella typhimurium salmonella enteritidis strain pt enteritidis dissemination inactivated salmonella intestinal tract typhimurium strain dt vaccine newcastle avinew live newcastle disease virus broiler chickens age one disease nd vggaavinew strain day active immunisation newcastle disease reduce mortality clinical signs associated disease future layer future breeder pullets age four weeks priming active immunisation egg drop caused newcastle disease vaccination inactivated vaccine strain ulster c prior beginning lay product portfolio animal health boehringer ingelheim livestock poultry continued companion animals horse main horse products focus prevention gastrogard ulcergard indicated treatment treatment parasite infestations management solutions prevention equine gastric ulcers one chronic diseases vaccines equine portfolio common diseases horses gastrogard also includes range flagship products treatment supplied easytouse oral paste form joint disease colic respiratory disease pain management first choice treatment gastric ulcers since nutraceuticals launch ulcergard usa preventive choice horses increased risk developing prascend indicated treatment pituitary gastric ulcers pars intermedia dysfunction ppid also known equine cushings disease clinical signs ppid eqvalanzimecterin contains ivermectin leading hypertrichiosis laminitis change body conformation ingredient controls wide variety important lack performance treatment prascend internal parasites including bots benzimidazole lifelong resistant small strongyles easytoadminister oral paste eqvalanzimecterin approved adult vetera vaccines first us vaccine portfolio horses foals young six weeks age include multiple convenient combinations disease pro tection horses young four months age eqvalan duogold zimecterin gold combines iver vaccines protect many nine infectious mectin praziquantel ingredient specifically organisms including influenza herpes west nile controls tapeworms virus tetanus others enables customised protec tion horse limited needle injections indications brand names active ingredients vaccine mareks prevexxionrn live herpes virus chimera vaccine recommended ovo disease serotype vaccination dayold strain rn embryonated chicken eggs protect virulent mareks dis ease vaccine newcastle newxxitek hvt nd live mareks disease vectored vaccination dayold mareks diseases virus serotype contains embryos onedayold chickens gene insert newcastle effective mareks disease disease newcastle disease vaccine includes diluent indications brand names active ingredients pituitary pars intermedia prascend pergolide mesylate symptomatic treatment clinical signs dysfunction ppid associated pituitary pars intermedia dysfunction ppid also known equine cushings disease combination vaccine vetera eastern western venezuelan vaccination healthy horses nine common diseases encephalomyelitis tetanus west aid prevention diseases caused horses nile virus equine included antigens us herpes virus equine canada influenza viruses treatment prevention gastrogard omeprazole treatment prevention recur equine gastric ulcers ulcergard rence gastric ulcers horses foals four weeks age older treatment prevention eqvalan ivermectin treatment parasitic infestations internal parasites horse zimecterin horses donkeys due large eqvalan gold ivermectin small strongyles ascarids eqvalan duo praziquantel zimecterin gold goldduo includes treatment tapeworms product portfolio animal health boehringer ingelheim companion animals pets pets portfolio offers diverse solutions nexgard spectra combines flea tick efficacy important needs canine feline health including afoxolaner nexgard broadspectrum industryleading parasiticides vaccines therapeutics deworming ingredient milbemycin oxime address major chronic diseases heart failure kidney beefflavoured chew nexgard spectra diseases epilepsy osteoarthritis effective treating fleas ticks also protects dogs deadly parasites heartworm lungworm years frontline leader well gastrointestinal parasites flea tick control dogs cats one trusted brands animal health frontline heartgard plus contains active ingredients continues bring innovation category ivermectin pyrantel soft beef chew given recent launch frontline triact features monthly ivermectin effective preventing deadly repellency insecticidal efficacy many disease heartworm disease pyrantel effective treatment carrying flying insects could decrease risk control round worms well hookworms transmission vectorborne pathogen heartgard launched first monthly heartworm preventative still bestselling nexgard contains active ingredient afoxolaner heartworm preventative world first oral medication treats fleas ticks dogs efficacy palatable beefflavoured soft chew formulation nexgard currently best selling pet medication animal health industry data file novel combination fipronil permethrin frontline triactfrontect reduces rick transmission babesia canis dermacentor reticulatus ehrlichia canis rhipicephalus sanguineus ticks dogs jongejan et al parasites vectors data file data file indications brand names active ingredients antiparasitic caninefeline frontline fipronil frontline indicated treat external parasites frontline combo ment prevention fleas ticks frontline plus chewing lice dogs cats aids frontline triact frontect control sarcoptic mange dogs antiparasitic canine external nexgard afoxolaner nexgard delivered highly parasites palatable beefflavoured chew kills adult fleas indicated treatment prevention flea infesta tions treatment control tick infestations dogs puppies one month antiparasitic canine internal nexgard spectra afoxolaner nexgard spectra delivered external parasites milbemycin oxime highly palatable beefflavoured chew kills adult fleas indicated treatment prevention flea tick infestations prevents heart worm disease treats controls hookworm roundworm whipworm lungworm infestations dogs puppies antiparasitic canine internal heartgard plus ivermectin use dogs prevent canine heart parasites pyrantel worm disease eliminating tissue stage heartworm larvae month days infection treatment control roundworms hookworms product portfolio animal health boehringer ingelheim companion animals pets continued first new class heart treatments termed variety formulations offers veterinarians inodilators vetmedin shown significantly owners flexibility use formulation prefer improve clinical signs extend life expectancy dogs individual cases manage various levels congestive heart failure originating dilated flammation pain associated licensed cardiomyopathy valvular insufficiency mitral andor indications tricuspid regurgitation recent studies also shown used preclinically appropriate asymptomatic pet vaccine product portfolio includes purevax cases either dilated cardiomyopathy valvular feline vaccines formulated provide effective protection insuf ficiency vetmedin significantly delays onset without use adjuvants clinical signs congestive heart failure metacam nonsteroidal antiinflammatory drug nsaid available oral suspension tablets injectable solution dogs oral suspension injectable solution cats dogs indications include alleviation inflammation pain acute chronic musculoskeletal disorders well reduction pain following surgery cats indica tions include alleviation inflammation pain acute chronic musculoskeletal disorders well alleviation mild moderate postoperative pain indications brand names active ingredients congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originating dilated cardio myo pathy valvular insufficiency mitral andor tricuspid regurgitation treatment dilated cardiomyopathy preclinical stage asymptomatic increase left ventricular endsystolic enddiastolic diameter dober man pinschers treatment dogs myxomatous mitral valve disease mmvd preclinical stage asymptomatic systolic mitral murmur evidence increased heart size delay onset clinical symptoms heart failure p inflammatory metacam meloxicam dogs metacam used reduce diseases postoperative pain inflammation following orthopaedic eg fracture operation soft tissue surgery cats metacam used reduce postoperative pain inflammation eg ovariohysterectomy spay operation orthopaedic minor soft tissue surgery moreover used alleviation pain inflammation acute chronic musculoskeletal disorders dogs cats feline vaccines portfolio purevax feline herpes virus purevax fully adjuvantfree feline calicivirus feline vaccine range provides feline panleukopenia virus optimised safety profile adjuvant chlamydophila free protection components felv rabies powerful immune response without adjuvant thanks innovative canarypox technology felv rabies easy fit cat lifestyles allow ing compliance feline vaccina tion guidelines sustained protection three years rabies component comparison balance sheet financial data boehringer ingelheim c h boehringer sohn ag co kg ingelheim comparison balance sheet financial data millions eur assets december intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets incl prepaid expenses deferred taxes liquid funds current assets incl prepaid expenses deferred taxes total assets liabilities equity december shareholders capital group reserves incl currency conversion difference equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions incl deferred taxes accounts payable loans incl prepaid expenses liabilities incl deferred taxes deferred charges total liabilities equity summary selected financial data net sales operating income operating income net sales income taxes income taxes net sales return equity equity ratio financial funds personnel expenses personnel expenses net sales average number employees research development expenses rd expenses net sales investments tangible assets depreciation tangible assets p r n c h boehringer sohn ag co kg assets december binger strae intangible assets ingelheim germany tangible assets telephone financial assets fax fixed assets contact inventories corporate division communications public affairs accounts receivable assets email pressboehringeringelheimcom incl prepaid expenses deferred taxes internet wwwboehringeringelheimcom liquid funds current assets incl prepaid expenses deferred taxes issued c h boehringer sohn ag co kg total assets concept design layout liabilities equity december mpm corporate communication solutions mainz wwwmpmde shareholders capital group reserves incl currency conversion difference photos equity attributable parent company andreas pohlmann noncontrolling interests printed group equity neue sddeutsche verlagsdruckerei gmbh ulm difference capital consolidation provisions incl deferred taxes copyright c h boehringer sohn ag co kg accounts payable loans incl prepaid expenses rights reserved part annual report may liabilities incl deferred taxes deferred charges reproduced transmitted form means total liabilities equity electronic photocopy without permission writing c h boehringer sohn ag co kg figures third parties used annual report based data available summary selected financial data time financial statement drawn net sales operating income operating income net sales income taxes income taxes net sales return equity equity ratio financial funds personnel expenses personnel expenses net sales average number employees research development expenses rd expenses net sales investments tangible assets depreciation tangible assets wwwboehringeringelheimcom annualreportboehringeringelheimcom